Drug Database · Clinicians

Pregabalin

Brands (116) Lyrica, Gablin, Pregab…Show all
Lyrica · Gablin · Pregab · Zonik · Epibalin ER · Funxion · Gabasyn · Pevesca · Sabalin · Unogab · Alvolin · Convuliz · Gablurica · K-Barin · Ligaba · Nervagest · Neurokem · Nurica · Pregadex · Pregard · Pregastat · Pregmed · Prelica · Prenaxon · Rhyma · Adobal 75 · Algabin 75 · Bagabrit · Convult · Fibrolin · Gabacon 150 · Gabacon 75 · Gabatreve · Gabi · Gabrix 150 · Gobalin · Gobeiz · Grabalin · Lalaca · Maxgalin 150 · Maxgalin 300 · Maxgalin 50 · Maxgalin 75 · Medirica · Nervica 150 · Nervica 25 · Nervica 75 · Nervilor 150 · Nervilor 75 · Nervolife · Neufar 150 · Neufar 75 · Neuralin 150 · Neuralin 75 · Neurica-75 · Neuro D 150 · Neuro D 75 · Neurobal-150 · Neurobal-75 · Neurolica · Neuroliz · Neuroprem · Neurorite · Neuroz · Neurozol 75 · Nurolin · Praxolin-150 · Praxolin-75 · Prebacare · Prebaga-75 · Prebamin 150 · Prebamin 75 · Prebawell-150 · Pregabagen · Pregabasaph-75 · Pregablex · Pregabur · Pregabur 150 · Pregalife · Pregamax-75 · Pregamed 150 · Pregamed-75 · Pregarich · Pregasafe · Pregav · Pregeb 150 · Pregeb 50 · Pregeb 75 · Pregeron · Preglibest · PreLoc 150 · PreLoc 75 · Prelynca 150 · Prelynca 50 · Prelynca 75 · Prenovalin · Preva · Probal 150 · Probal 75 · Rebalin 150 · Rebalin 75 · Regabalin · Regabin 75 · Regobal · Retabalin-R · Retabaline · Stagalin · Sunpreg 150 · Sunpreg 75 · Topglin 150 · Topglin 75 · Valicon · Vexer 150 · Vexer 50 · Vexer 75 · Zyzyx

Antiepileptic/Analgesic; Antiepileptic (gabapentinoids); and others PH FDA category

Rx · Prescription drug188 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID d4734e7d-5079-455e-8ff5-8f4539c998a9, version date April 15, 2025 (Lyrica · Viatris Specialty LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
  • Postherpetic neuralgia (PHN)
  • Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older
  • Fibromyalgia
  • Neuropathic pain associated with spinal cord injury
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE LYRICA is indicated for:

  • Management of neuropathic pain associated with diabetic peripheral neuropathy
  • Management of postherpetic neuralgia
  • Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older
  • Management of fibromyalgia
  • Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for:
  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) (1)
  • Postherpetic neuralgia (PHN) (1)
  • Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older (1)
  • Fibromyalgia (1)
  • Neuropathic pain associated with spinal cord injury (1)

Contraindications

  • Known hypersensitivity to pregabalin or any component
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.2)]. • Known hypersensitivity to pregabalin or any of its components. (4)

Dosing: Adult

  • Diabetic peripheral neuropathic pain: Start 150 mg/day in 3 doses; 300 mg/day within 1 week (maximum 300 mg/day)
  • Postherpetic neuralgia: Start 150 mg/day in 2 or 3 doses; 300 mg/day within 1 week; maximum 600 mg/day
  • Fibromyalgia: Start 150 mg/day in 2 doses; 300 mg/day within 1 week; maximum 450 mg/day
  • Adjunct for partial-onset seizures (30 kg or more): Start 150 mg/day in 2 or 3 doses; maximum 600 mg/day
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • • For adult indications, begin dosing at 150 mg/day. For partial‑onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4. (2.2, 2.3, 2.4, 2.5, 2.6)
  • • Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain (2.2)
  • 3 divided doses per day 300 mg/day within 1 week. PHN (2.3)
  • 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial‑Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More (2.4)
  • 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial‑Onset Seizures in Pediatric Patients Weighing Less than 30 kg (2.4)
  • 1 month to less than 4 years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia (2.5)
  • 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury (2.6)
  • 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. • Dose should be adjusted in adult patients with reduced renal function. (2.7)
2.1 Important Administration Instructions

2.1 Important Administration Instructions LYRICA is given orally with or without food. When discontinuing LYRICA, taper gradually over a minimum of 1 week [see Warnings and Precautions (5.4)]. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function [see Dosage and Administration (2.7)].

2.2 Neuropathic Pain Associated with Diabetic Peripheral

2.2 Neuropathic Pain Associated with Diabetic Peripheral Neuropathy in Adults The maximum recommended dose of LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional significant benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 300 mg/day is not recommended [see Adverse Reactions (6.1)].

2.3 Postherpetic Neuralgia in Adults

2.3 Postherpetic Neuralgia in Adults The recommended dose of LYRICA is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day, and who are able to tolerate LYRICA, may be treated with up to 300 mg two times a day, or 200 mg three times a day (600 mg/day). In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, reserve dosing above 300 mg/day for those patients who have on-going pain and are tolerating 300 mg daily [see Adverse Reactions (6.1)].

2.4 Adjunctive Therapy for Partial-Onset Seizures in Patients 1 Month of Age and Older

2.4 Adjunctive Therapy for Partial-Onset Seizures in Patients 1 Month of Age and Older The recommended dosages for adults and pediatric patients 1 month of age and older are included in Table 1. Administer the total daily dosage orally in two or three divided doses as indicated in Table 1. In pediatric patients, the recommended dosing regimen is dependent upon body weight.

Based on clinical response and tolerability, dosage may be increased, approximately weekly. Table 1. Recommended Dosage for Adults and Pediatric Patients 1 Month and Older Age and Body Weight Recommended Initial Dosage Recommended Maximum Dosage Frequency of Administration Adults (17 years and older) 150 mg/day 600 mg/day 2 or 3 divided doses Pediatric patients weighing 30 kg or more 2.5 mg/kg/day 10 mg/kg/day (not to exceed 600 mg/day) 2 or 3 divided doses Pediatric patients weighing less than 30 kg 3.5 mg/kg/day 14 mg/kg/day 1 month to less than 4 years of age: 3 divided doses 4 years of age and older: 2 or 3 divided doses Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related.

The effect of dose escalation rate on the tolerability of LYRICA has not been formally studied. The efficacy of adjunctive LYRICA in patients taking gabapentin has not been evaluated in controlled trials. Consequently, dosing recommendations for the use of LYRICA with gabapentin cannot be offered.

2.5 Management of Fibromyalgia in Adults

2.5 Management of Fibromyalgia in Adults The recommended dose of LYRICA for fibromyalgia is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).

Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional benefit and this dose was less well tolerated. In view of the dose‑dependent adverse reactions, treatment with doses above 450 mg/day is not recommended [see Adverse Reactions (6.1)].

2.6 Neuropathic Pain Associated with Spinal Cord Injury in Adults

2.6 Neuropathic Pain Associated with Spinal Cord Injury in Adults The recommended dose range of LYRICA for the treatment of neuropathic pain associated with spinal cord injury is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.

Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate LYRICA may be treated with up to 300 mg two times a day [see Clinical Studies (14.5)].

2.7 Dosing for Adult Patients with Renal Impairment

2.7 Dosing for Adult Patients with Renal Impairment In view of dose-dependent adverse reactions and since LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function. The use of LYRICA in pediatric patients with compromised renal function has not been studied. Base the dose adjustment in patients with renal impairment on creatinine clearance (CLcr), as indicated in Table 2.

To use this dosing table, an estimate of the patient’s CLcr in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation: Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CLcr greater than or equal to 60 mL/min).

Then refer to Table 2 to determine the corresponding renal adjusted dose. (For example: A patient initiating LYRICA therapy for postherpetic neuralgia with normal renal function (CLcr greater than or equal to 60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CLcr of 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.) For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function.

In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see Table 2). Table 2. Pregabalin Dosage Adjustment Based on Renal Function TID = Three divided doses; BID = Two divided doses; QD = Single daily dose. Creatinine Clearance (CLcr) (mL/min) Total Pregabalin Daily Dose (mg/day) Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.

Dose Regimen Greater than or equal to 60 150 300 450 600 BID or TID 30-60 75 150 225 300 BID or TID 15-30 25-50 75 100-150 150 QD or BID Less than 15 25 25-50 50-75 75 QD Supplementary dosage following hemodialysis (mg) Supplementary dose is a single additional dose. Patients on the 25 mg QD regimen: take one supplemental dose of 25 mg or 50 mg Patients on the 25-50 mg QD regimen: take one supplemental dose of 50 mg or 75 mg Patients on the 50-75 mg QD regimen: take one supplemental dose of 75 mg or 100 mg Patients on the 75 mg QD regimen: take one supplemental dose of 100 mg or 150 mg Cockcroft and Gault Equation

Dosing: Altered kidney function

Pregabalin is cleared mainly by the kidneys, and its clearance is nearly proportional to creatinine clearance (CrCl). The US label scales the total daily dose to CrCl and adds a supplemental dose after each 4-hour hemodialysis session.

Kidney function measure: Label uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault).

Show full dosing details
CrCl ≥60 mL/min
Total daily dose 150, 300, 450 or 600 mg/day in 2 or 3 divided doses, by indication (label).
CrCl 30–59 mL/min
Label band CrCl 30–60: 75, 150, 225 or 300 mg/day in 2 or 3 divided doses (half the normal-function dose).
CrCl 15–29 mL/min
Label band CrCl 15–30: 25–50, 75, 100–150 or 150 mg/day, once daily or in 2 divided doses. Start at the bottom of the range (25–75 mg/day in CrCl <30 / HD) and titrate slowly; altered mental status and falls are increased in HD patients (Ishida 2018; Muanda 2022).
CrCl <15 mL/min (not on dialysis)
25, 25–50, 50–75 or 75 mg/day as a single daily dose (label). Start at the bottom of the range (25–75 mg/day in CrCl <30 / HD) and titrate slowly; altered mental status and falls are increased in HD patients (Ishida 2018; Muanda 2022).
Hemodialysis (intermittent)
Dose by CrCl as above, plus one supplemental dose right after every 4-hour hemodialysis: 25 mg/day regimen, 25 or 50 mg; 25–50 mg/day, 50 or 75 mg; 50–75 mg/day, 75 or 100 mg; 75 mg/day, 100 or 150 mg (label). Start at the bottom of the range (25–75 mg/day in CrCl <30 / HD) and titrate slowly; altered mental status and falls are increased in HD patients (Ishida 2018; Muanda 2022).
Peritoneal dialysis
Not studied in peritoneal dialysis (no label data). Clinical extrapolation: the CrCl <15 regimen is a cautious starting point, with specialist input.
CRRT
No data in label. Insufficient data: specialist input.
  • Dialyzable? Yes: about 50% removed in a 4-hour hemodialysis session (label).
  • Monitoring Dizziness, somnolence, edema, respiratory depression (especially with opioids or other central nervous system depressants). Altered mental status and falls are more common in hemodialysis patients (Ishida 2018).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Normal kidney function: usual pediatric dosing (label).
eGFR 30–59
Not studied in children with reduced kidney function (label). Specialist input.
eGFR 15–29
Not studied in children with reduced kidney function (label). Specialist input.
eGFR <15 (not on dialysis)
Not studied in children with reduced kidney function (label). Specialist input.
Hemodialysis (intermittent)
Not studied. Specialist input.
Peritoneal dialysis
Not studied.
CRRT
Not studied.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.7 Dosing for Adult Patients with Renal Impairment In view of dose-dependent adverse reactions and since LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function. The use of LYRICA in pediatric patients with compromised renal function has not been studied. Base the dose adjustment in patients with renal impairment on creatinine clearance (CLcr), as indicated in Table 2.

To use this dosing table, an estimate of the patient’s CLcr in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation: Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CLcr greater than or equal to 60 mL/min).

Then refer to Table 2 to determine the corresponding renal adjusted dose. (For example: A patient initiating LYRICA therapy for postherpetic neuralgia with normal renal function (CLcr greater than or equal to 60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CLcr of 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.) For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function.

In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see Table 2). Table 2. Pregabalin Dosage Adjustment Based on Renal Function TID = Three divided doses; BID = Two divided doses; QD = Single daily dose. Creatinine Clearance (CLcr) (mL/min) Total Pregabalin Daily Dose (mg/day) Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.

Dose Regimen Greater than or equal to 60 150 300 450 600 BID or TID 30-60 75 150 225 300 BID or TID 15-30 25-50 75 100-150 150 QD or BID Less than 15 25 25-50 50-75 75 QD Supplementary dosage following hemodialysis (mg) Supplementary dose is a single additional dose. Patients on the 25 mg QD regimen: take one supplemental dose of 25 mg or 50 mg Patients on the 25-50 mg QD regimen: take one supplemental dose of 50 mg or 75 mg Patients on the 50-75 mg QD regimen: take one supplemental dose of 75 mg or 100 mg Patients on the 75 mg QD regimen: take one supplemental dose of 100 mg or 150 mg Cockcroft and Gault Equation

8.6 Renal Impairment LYRICA is eliminated primarily by renal excretion and dose adjustment is recommended for adult patients with renal impairment [see Dosage and Administration (2.7) and Clinical Pharmacology (12.3)]. The use of LYRICA in pediatric patients with compromised renal function has not been studied.

Dosing: Pediatric

Approved ages
Adjunctive therapy for partial-onset seizures: 1 month and older. Neuropathic pain and fibromyalgia: not established in children (label).
Usual dose
Partial-onset seizures: weight 30 kg or more, start 2.5 mg/kg/day, maximum 10 mg/kg/day (not to exceed 600 mg/day), 2 or 3 divided doses. Under 30 kg, start 3.5 mg/kg/day, maximum 14 mg/kg/day; 3 divided doses under 4 years, 2 or 3 doses from 4 years (label).
Maximum dose
10 mg/kg/day (≥30 kg; not to exceed 600 mg/day) or 14 mg/kg/day (<30 kg) (label).
Neonates
Neonates (under 1 month): not established (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Neuropathic Pain Associated with Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Neuropathic Pain Associated with Spinal Cord Injury Safety and effectiveness in pediatric patients have not been established. Fibromyalgia Safety and effectiveness in pediatric patients have not been established.

A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years, at LYRICA total daily doses of 75‑450 mg per day. The primary efficacy endpoint of change from baseline to Week 15 in mean pain intensity (derived from an 11‑point numeric rating scale) showed numerically greater improvement for the pregabalin‑treated patients compared to placebo‑treated patients, but did not reach statistical significance.

The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia. Adjunctive Therapy for Partial-Onset Seizures Safety and effectiveness in pediatric patients below the age of 1 month have not been established. 4 to Less Than 17 Years of Age with Partial-Onset Seizures The safety and effectiveness of LYRICA as adjunctive treatment for partial‑onset seizures in pediatric patients 4 to less than 17 years of age have been established in a 12-week, double-blind, placebo-controlled study (n=295) [see Clinical Studies (14.3)].

Patients treated with LYRICA 10 mg/kg/day had, on average, a 21.0% greater reduction in partial‑onset seizures than patients treated with placebo (p=0.0185). Patients treated with LYRICA 2.5 mg/kg/day had, on average, a 10.5% greater reduction in partial‑onset seizures than patients treated with placebo, but the difference was not statistically significant (p=0.2577).

Responder rates (50% or greater reduction in partial‑onset seizure frequency) were a key secondary efficacy parameter and showed numerical improvement with LYRICA compared with placebo: the responder rates were 40.6%, 29.1%, and 22.6%, for LYRICA 10 mg/kg/day, LYRICA 2.5 mg/kg/day, and placebo, respectively. The most common adverse reactions (≥5%) with LYRICA in this study were somnolence, weight increased, and increased appetite [see Adverse Reactions (6.1)].

The use of LYRICA 2.5 mg/kg/day in pediatric patients is further supported by evidence from adequate and well‑controlled studies in adults with partial-onset seizures and pharmacokinetic data from adult and pediatric patients [see Clinical Pharmacology (12.3)]. 1 Month to Less than 4 Years of Age with Partial-Onset Seizures The safety and effectiveness of LYRICA as adjunctive treatment for partial‑onset seizures in pediatric patients 1 month to less than 4 years of age have been established in a 14‑day double‑blind, placebo-controlled study (N=175) [see Clinical Studies (14.3)]. The youngest subject evaluated was 3 months of age; use in patients 1 month to less than 3 months of age is supported by additional pharmacokinetic analyses.

Patients treated with LYRICA 14 mg/kg/day had, on average, 43.9% greater reduction in partial‑onset seizures than patients treated with placebo (p=0.0223). In addition, pediatric patients treated with LYRICA 14 mg/kg/day showed numerical improvement in responder rates (≥50% reduction in partial‑onset seizure frequency) compared with placebo (53.6% versus 41.5%).

Patients treated with LYRICA 7 mg/kg/day did not show improvement relative to placebo for either endpoint. The most common dose‑related adverse reactions (> 5%) with LYRICA in this study were somnolence, pneumonia, and viral infection [see Adverse Reactions (6.1)]. Juvenile Animal Data In studies in which pregabalin (50 to 500 mg/kg) was orally administered to young rats from early in the postnatal period (Postnatal Day 7) through sexual maturity, neurobehavioral abnormalities (deficits in learning and memory, altered locomotor activity, decreased auditory startle responding and habituation) and reproductive impairment (delayed sexual maturation and decreased fertility in males and females) were observed at doses greater than or equal to 50 mg/kg.

The neurobehavioral changes of acoustic startle persisted at greater than or equal to 250 mg/kg and locomotor activity and water maze performance at greater than or equal to 500 mg/kg in animals tested after cessation of dosing and, thus, were considered to represent long-term effects. The low effect dose for developmental neurotoxicity and reproductive impairment in juvenile rats (50 mg/kg) was associated with a plasma pregabalin exposure (AUC) approximately equal to human exposure at the maximum recommended dose of 600 mg/day.

A no-effect dose was not established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In controlled clinical studies of LYRICA in neuropathic pain associated with diabetic peripheral neuropathy, 246 patients were 65 to 74 years of age, and 73 patients were 75 years of age or older. In controlled clinical studies of LYRICA in neuropathic pain associated with postherpetic neuralgia, 282 patients were 65 to 74 years of age, and 379 patients were 75 years of age or older.

In controlled clinical studies of LYRICA in epilepsy, there were only 10 patients 65 to 74 years of age, and 2 patients who were 75 years of age or older. No overall differences in safety and efficacy were observed between these patients and younger patients. In controlled clinical studies of LYRICA in fibromyalgia, 106 patients were 65 years of age or older.

Although the adverse reaction profile was similar between the two age groups, the following neurological adverse reactions were more frequent in patients 65 years of age or older: dizziness, vision blurred, balance disorder, tremor, confusional state, coordination abnormal, and lethargy. LYRICA is known to be substantially excreted by the kidney, and the risk of toxic reactions to LYRICA may be greater in patients with impaired renal function.

Because LYRICA is eliminated primarily by renal excretion, adjust the dose for elderly patients with renal impairment [see Dosage and Administration (2.7)].

Administration

2.1 Important Administration Instructions LYRICA is given orally with or without food. When discontinuing LYRICA, taper gradually over a minimum of 1 week [see Warnings and Precautions (5.4) ] . Because LYRICA is eliminated primarily by renal excretion, adjust the dose in adult patients with reduced renal function [see Dosage and Administration (2.7) ].

US FDA label

Dosage forms

Philippines

  • Capsule: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 300 mg
  • Extended-release tablet: 82.5 mg, 165 mg, 330 mg
  • Hard gelatin capsule: 75 mg
  • Sustained-release capsule: 300 mg

Registered products in the Philippines

188 products registered with the Food and Drug Administration (FDA) Philippines list Pregabalin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products188
Philippine FDA-registered products for Pregabalin
Package insert
Adobal 75Pregabalin
75 mg CapsuleAlu-Alu Blister Pack of 10's (Box of 10's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15642
Aug 13, 2029
Algabin 75Pregabalin
75 mg CapsuleAlu PVDC x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Foramen Products Corporation
DRP-7631-01
Sep 19, 2031
AlvolinPregabalin
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd. (Indrad Plant)India
Metro Drug, Inc.
DR-XY46134
Oct 26, 2027
AlvolinPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd. (Indrad Plant)India
METRO DRUG,INC.Trader: ALVOGEN Asia Pacific Holdings Limited
DR-XY46135
Oct 26, 2027
BagabritPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Britton Distributions, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13209-01
Dec 29, 2027
ConvulizPregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY49246
Oct 9, 2029
ConvulizPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY47543
Nov 17, 2036
ConvultPregabalin
75 mg CapsuleAlu/PVC blister pack x 10's Box of 10's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-8750
Feb 21, 2030
Epibalin ERPregabalin
165 mg Extended-Release TabletAlu/Alu blister pack of 10 tablets (box of 10, 30 and 100 tablets)
RxVAT-exempt
MSN. Laboratories Private Limited (Formulations Division, Unit-II)India
MSN Labs Philippines, Inc.
DR-XY49181
Aug 29, 2029
Epibalin ERPregabalin
330 mg Extended-Release TabletAlu/Alu blister pack of 10 tablets (box of 10, 30 and 100 tablets)
RxVAT-exempt
MSN Laboratories Private Limited (Formulations Division, Unit-II)India
MSN Labs Philippines, Inc.
DR-XY49182
Aug 29, 2029
Epibalin ERPregabalin
82.5 mg Extended-Release TabletAlu/Alu blister pack of 10 tablets (box of 10, 30, and 100 tablets)
RxVAT-exempt
MSN Laboratories Private LimitedIndia
MSN Labs Philippines Inc.
DR-XY49266
Nov 4, 2029
FibrolinPregabalin
75mg CapsuleAlu/PVC Clear Blister Pack x 10’s (Box of 30’s, 50’s and 100’s)
RxVAT-exempt
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-19043
Oct 21, 2031
FunxionPregabalin
150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma Ltd.India
UNILAB, Inc.
DR-XY41216
Sep 11, 2030
FunxionPregabalin
50 mg CapsuleAlu/ PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
UNILAB, Inc.
DR-XY42185
Jul 8, 2028
FunxionPregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
UNILAB, Inc.
DR-XY41215
Sep 11, 2030
Gabacon 150Pregabalin
150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's, 30's 60's and 100's)
RxVAT-exempt
Coral Laboratories Ltd.India
Despina Pharma Inc.
DRP-17068
Sep 23, 2030
Gabacon 75Pregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's, 30's 60's and 100's)
RxVAT-exempt
Coral Laboratories Ltd.India
Despina Pharma Inc.
DRP-17069
Oct 10, 2030
GabasynPregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-12414
Aug 4, 2027
GabasynPregabalin
50 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-12413
Aug 4, 2027
GabasynPregabalin
75 mg CapsuleAlu/Clear PVC Blister x 10's (Box of 10 blister packs)
RxVAT-exempt
Sydenham Laboratories, Inc.Philippines
—
DRP-11956
May 24, 2027
GabatrevePregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Tri-Eve Pharmaceutical MarketingImporter: Ambica International Corporation
DRP-8025-03
Nov 19, 2028
GabiPregabalin
75 mg CapsulePVC/PVDC/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
Genveon Ilac Sanayi ve Tic. A.STurkey
Importer: Sandoz Philippines Corporation
DRP-6198
Jul 10, 2030
GablinPregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's. Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
The Cathay YSS Distributors Co., IncImporter: Medinova Pharmaceutical Inc.
DRP-13155-01
Dec 12, 2027
GablinPregabalin
75 mg CapsuleAlu/Alu Blister Pack X 7’s (Box of 28’s)
RxVAT-exempt
Gracure Pharmaceutical Ltd.India
The Cathay Yss Distributors Co., IncImporter: Aglobal Care, Inc.
DRP-11381-02
Mar 25, 2031
GablinPregabalin
75 mg CapsulePVC/PVDC/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
Genveon İlaç Sanayi Ve Tic. A.Ş.Turkey
The Cathay Yss Distributors Co., Inc.Importer: Sandoz Philippines Corporation
DRP-6198-02
Aug 7, 2031
GablinPregabalin
75mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's, Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
The Cathay YSS Distributors Co., IncImporter: Medinova Pharmaceutical Inc.
DRP-13209-04
Dec 29, 2027
GabluricaPregabalin
150 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-8024
Nov 19, 2028
GabluricaPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-8025
Nov 19, 2028
Gabrix 150Pregabalin
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
Amb HK Enterprises Inc.
DRP-16622
May 21, 2030
GobalinPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro labs LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Brown & Burk Philippines Inc.
DRP-8432-01
Jan 9, 2028
GobeizPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13209-03
Dec 29, 2027
GrabalinPregabalin
75 mg CapsuleAlu/Alu Blister Pack X 7’s (Box of 14’s, 28’s and 98’s)
RxVAT-exempt
Gracure Pharmaceutical Ltd.India
Aglobal Care, Inc.
DRP-11381
Jul 24, 2030
K-BarinPregabalin
150 mg CapsuleAlu/PVC blister pack of 10's (Box of 30's and 60's)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Medethix, Inc.
DRP-8347
Aug 20, 2029
K-BarinPregabalin
75 mg CapsuleAlu/PVC blister pack of 10's (Box of 30's); Alu/PVC blister pack of 10's (Box of 60's)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
BELL-KENZ PHARMA INC.Importer: Medethix, Inc.
DRP-8346
Aug 20, 2029
LalacaPregabalin
75mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Yooyoung Pharmaceutical Co., Ltd.Korea
JLT Pharma, Inc.
DRP-11149
Feb 10, 2027
LigabaPregabalin
150 mg CapsuleAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
MSN Laboratories Private Limited (Formulations Division)India
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DR-XY45033
Feb 3, 2031
LigabaPregabalin
75 mg CapsuleAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
MSN Laboratories Private Limited (Formulations Division)India
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DR-XY45032
Feb 3, 2031
LyricaPregabalin
150mg capsuleAlu/PVC clear blister pack x 14's (Box of 56's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-6120
Dec 11, 2027
LyricaPregabalin
25 mg CapsuleAlu/ PVC clear blister x 14's (Box of 56's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-16152
Dec 11, 2027
LyricaPregabalin
25mg CapsuleAlu/PVC clear blister x 14's Box of 56's
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DR-XY32505
Dec 11, 2027
LyricaPregabalin
50mg CapsuleAlu/PVC clear blister pack x 14's Box of 56's
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-6121
Dec 11, 2027
LyricaPregabalin
75mg CapsuleAlu/PVC clear blister pack x 14's Box of 56's
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Viatris, Inc.
DRP-6119
Dec 11, 2027
Maxgalin 150Pregabalin
150 mg CapsuleAlu/PVC Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-15480
Jul 31, 2029
Maxgalin 300Pregabalin
300 mg CapsuleAlu/PVC Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-15479
Jul 15, 2029
Maxgalin 50Pregabalin
50 mg CapsuleAlu/PVC Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-15482
Jul 15, 2029
Maxgalin 75Pregabalin
75 mg CapsuleAlu/PVC Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DRP-15481
Jul 15, 2029
MediricaPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack X 10's (Box of 30's; Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-13209-05
Dec 29, 2027
NervagestPregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
SAMJIN PHARMACEUTICAL CO., LTD.Republic of Korea
NATRAPHARM, INC.
DR-XY44615
Jun 4, 2030
NervagestPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Samjin Pharmaceutical Co., Ltd.Republic of Korea
Natrapharm, Inc.
DR-XY44616
Jun 4, 2030
Nervica 150Pregabalin
150 mg CapsuleAlu-PVC/PVDC Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Unison Laboratories Co. Ltd.Thailand
Justright Healthcare Inc.
DR-XY48480
Nov 24, 2027
Nervica 25Pregabalin
25 mg CapsuleAlu-PVC/PVDC Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY48812
Jul 21, 2028
Nervica 75Pregabalin
75 mg CapsuleAlu-PVC/PVDC Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY48813
Jul 21, 2028
Nervilor 150Pregabalin
150mg CapsuleALU-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Kopran LimitedIndia
Despina Pharma Inc.
DRP-15745
Sep 11, 2029
Nervilor 75Pregabalin
75 mg CapsuleALU-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Kopran LimitedIndia
Despina Pharma Inc.
DRP-15746
Sep 11, 2029
NervolifePregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack X 10's (Box of 30's; Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc.
DRP-13209-07
Dec 29, 2027
Neufar 150Pregabalin
150 mg CapsuleAlu/Alu Strip Foil x 10's (Box of 30's)
RxVAT-exempt
PT. Pratapa NirmalaIndonesia
Exa Life Care Pharma Inc.
DRP-12830
Oct 26, 2027
Neufar 75Pregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 capsules)
RxVAT-exempt
PT. Pratapa NirmalaIndonesia
Exa Life Care Pharma Inc.
DRP-12899
Oct 26, 2027
Neuralin 150Pregabalin
150 mg CapsuleAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15588
Aug 7, 2029
Neuralin 75Pregabalin
75mg CapsuleAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15638
Aug 13, 2029
Neurica-75Pregabalin
75 mg capsuleAlu/Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-8432
Jan 9, 2028
Neuro D 150Pregabalin
150mg CapsuleClear Alu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Steril-Gene Life Sciences (P) Ltd.India
Despina Pharma Inc.
DRP-12472
Aug 16, 2027
Neuro D 75Pregabalin
75 mg CapsuleClear Alu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Steril-Gene Life Sciences (P) Ltd.India
Despina Pharma Inc.
DRP-12484
Aug 18, 2027
Neurobal-150Pregabalin
150 mg CapsuleAlu-PVDC/PVC Blister Pack x 10's (Box of 30's) x 10's (Box of 30's)
RxVAT-exempt
The Madras PharmaceuticalsIndia
Aglobal Care, Inc.
DRP-12966
Nov 10, 2027
Neurobal-75Pregabalin
75 mg CapsuleAlu-PVDC/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The Madras PharmaceuticalsIndia
Aglobal Care, Inc.
DRP-12967
Nov 10, 2027
NeurokemPregabalin
150 mg CapsuleAlu/Alu blister pack x 10 capsules (Box of 10 capsules)
RxVAT-exempt
Alkem Laboratories Ltd.India
Alkem Laboratories Corporation
DR-XY47875
Mar 31, 2027
NeurokemPregabalin
150 mg CapsuleAlu-Alu blister pack x 10's ( Box of 10's )
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Alkem Laboratories CorporationImporter: Genedrift Philippines OPC
DRP-6928-04
Nov 21, 2026
NeurolicaPregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Dagon Pharmaceuticals Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-18559
Jul 30, 2031
NeurolizPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY47544
Nov 17, 2031
NeuropremPregabalin
75 mg CapsuleAlu/ Alu Blister Pack x 10’s (Box of 30's and 100’s)
RxVAT-exempt
Globela Pharma Private LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-13997-01
Jun 1, 2028
NeuroritePregabalin
75mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-13997
Jun 1, 2028
NeurozPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Zydus Healthcare Philippines, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-6592-02
Mar 15, 2031
Neurozol 75Pregabalin
75 mg CapsuleAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s, 60's and 100's)
RxVAT-exempt
Kopran LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-15746-01
Sep 11, 2029
NonePregabalin
150 mg CapsuleAlu/PVC Clear Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Philusa CorporationImporter: Viatris, Inc.
DRP-6120-01
Dec 11, 2027
NonePregabalin
150 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Ambica International Corporation
DRP-8024-02
Nov 19, 2028
NonePregabalin
150 mg CapsuleAlu/PVC blister pack of 10's Box of 30's and 60's
RxVAT-exempt
Genuone Science Inc.Republic of Korea
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-8347-01
Aug 20, 2029
NonePregabalin
50 mg CapsuleAlu/PVC Clear Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Philusa CorporationImporter: Viatris, Inc.
DRP-6121-01
Dec 11, 2027
NonePregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 98's)
RxVAT-exempt
Gracure Pharmaceutical Ltd.India
TGP Pharma IncImporter: Aglobal Care, Inc
DRP-11381-01
Jul 20, 2031
NonePregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-13209-02
Dec 29, 2027
NonePregabalin
75 mg CapsuleAlu/PVC Clear Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Philusa CorporationImporter: Viatris, Inc.
DRP-6119-01
Dec 11, 2027
NonePregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-6592-03
Mar 6, 2031
NonePregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Aju Pharm. Co., Ltd.Korea
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-6800
Aug 18, 2031
NonePregabalin
75 mg CapsuleAlu/ Alu Blister Pack x 10’s (Box of 10’s)
RxVAT-exempt
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-7038
Feb 1, 2031
NonePregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Ambica International Corporation
DRP-8025-04
Nov 19, 2028
NonePregabalin
75 mg CapsuleAlu/PVC blister pack of 10's (Box of 30's); Alu/PVC blister pack of 10's (Box of 60's)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
I.E. Medica, IncImporter: Medethix, Inc.
DRP-8346-01
Aug 20, 2029
NonePregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Micro Labs LimitedIndia
Actimed, Inc.Importer: Brown & Burk Philippines, Inc.
DRP-8432-02
Jan 9, 2028
NonePregabalin
75 mg CapsuleAlu / PVC blister pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Reta DrugImporter: Ambica International Corporation
DRP-8750-02
Feb 21, 2030
NonePregabalin
75 mg CapsuleAlu / PVC blister pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-8750-03
Feb 21, 2030
NonePregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
South Star DrugImporter: Ambica International Corporation
DRP-8750-04
Feb 21, 2030
NuricaPregabalin
300 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 14's)
RxVAT-exempt
Macter International Ltd.Pakistan
Sahar International Trading, Inc.
DR-XY48741
May 24, 2028
NuricaPregabalin
75mg CapsuleAlu/Alu Blister Pack x 7's (Box of 14's)
RxVAT-exempt
Macter International Ltd.Pakistan
Sahar International Trading Inc.
DR-XY49690
Apr 14, 2031
NurolinPregabalin
50mg CapsuleAlu/PVC Blister Pack x 10's (Box of 3 blister packs x 10 capsules; Box of 10 blister packs x 10 capsules)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-12585
Sep 8, 2027
PevescaPregabalin
150 mg CapsuleAlu/PVC Blister Pack x 14's (Box of 4 blister packs x 14 tablets)
RxVAT-exempt
İlko İlaç San. Ve Tic.A.S.Turkey
Suhitas Pharmaceuticals Inc.
DRP-12375
Jul 28, 2027
PevescaPregabalin
300 mg CapsuleAlu/PVC Blister Pack x 14's (Box of 4 blister packs x 14 tablets)
RxVAT-exempt
İlko İlaç San. Ve Tic.A.S.Turkey
Suhitas Pharmaceuticals Inc.
DRP-12376
Jul 28, 2027
PevescaPregabalin
75 mg CapsuleAlu/PVC Blister Pack x 14's (Box of 4 blister packs x 14 tablets)
RxVAT-exempt
İlko İlaç San. Ve Tic.A.S.Turkey
Suhitas Pharmaceuticals Inc.
DRP-12377
Jul 28, 2027
Praxolin-150Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Despina Pharma Inc.
DRP-15662
Aug 15, 2029
Praxolin-75Pregabalin
75 mg CapsuleAlu/Clear PVC Blister pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Despina Pharma Inc.
DRP-15804
Sep 26, 2029
PrebacarePregabalin
75 mg CapsuleAlu/PVC blister pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medcare PharmaceuticalsImporter: Ambica International Corporation
DRP-8750-05
Feb 21, 2030
Prebaga-75Pregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 1's)
RxVAT-exempt
Zim Laboratories LimitedIndia
Progen Pharmaceutical DistributorsImporter: Biocare Lifesciences, Inc.
DRP-11035
Jan 11, 2027
Prebamin 150Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) (Box of 60's)
RxVAT-exempt
Sunglow Lifesciences Private LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-13838-01
Apr 27, 2028
Prebamin 75Pregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 30’s & 60’s)
RxVAT-exempt
Sunglow Lifesciences Private LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma Inc.
DRP-13647-01
Mar 22, 2028
Prebawell-150Pregabalin
150 mg Capsule
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-6928-02
Nov 21, 2026
PregabPregabalin
150 mg CapsuleBlister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Docteur's Choice Corporation
DRP-12419
Aug 8, 2027
PregabPregabalin
25 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Docteur's Choice Corporation
DRP-13884
May 11, 2028
PregabPregabalin
50 mg CapsuleAlu/Clear PVC blister pack x 10's (Box of 1 Blister pack x 10 Capsules; Box of 3 Blister packs x 10 Capsules;Box of 10 Blister Packs x 10 Capsules)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Docteur'S Choice Corporation
DRP-12656
Sep 19, 2027
PregabPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 1 blister pack x 10 tablets; 3 blister packs x 10 tablets; 10 blister packs x 10 tablets)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Docteur's Choice Corporation
DRP-12793
Oct 7, 2027
PregabagenPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Medchoice Distribution, Inc.Importer: Ambica International Corporation
DRP-8025-01
Nov 19, 2028
Pregabasaph-75Pregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-11196
Jan 23, 2031
PregablexPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Metrogen Pharma Philippines, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-6592-01
Mar 16, 2031
PregaburPregabalin
75 mg CapsuleAlu/PVDC Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Ambica International Corporation
DRP-8750-01
Feb 21, 2030
Pregabur 150Pregabalin
150 mg CapsuleAlu-alu blister pack x 10's (Box of 10's)
RxVAT-exempt
Rhydburg Pharmaceutical Ltd.India
Importer: Genedrift Philippines OPC
DRP-6928
Nov 21, 2026
PregadexPregabalin
150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
PT. Dexa MedicaIndonesia
Importer: Glorious Dexa Mandaya, Inc.
DRP-8081
Oct 5, 2027
PregadexPregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
PT. DEXA MEDICAIndonesia
Importer: GLORIOUS DEXA MANDAYA, INC.
DRP-8079
Oct 5, 2027
PregalifePregabalin
75 mg CapsuleAlu/Alu Blister pack of 10's (Box of 30's and 100's)
RxVAT-exempt
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-16796
Jul 18, 2030
Pregamax-75Pregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 14's); Alu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Gracure Pharmaceutical Ltd.India
Dreamax Incorporated
DRP-8707
Feb 7, 2030
Pregamed 150Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-13155
Dec 12, 2027
Pregamed-75Pregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-13209
Dec 29, 2027
PregardPregabalin
150 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DRP-7558
Apr 7, 2030
PregardPregabalin
75 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DRP-7557
Jun 14, 2031
PregarichPregabalin
75 mg CapsuleAlu PVDC x 10's (Box of 30's & Box of 50's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Foramen Products Corporation
DRP-7631-02
Sep 22, 2031
PregasafePregabalin
75mg CapsuleAlu/PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
MSN Laboratories Private LimitedIndia
MSN Labs Philippines Inc.
DRP-8329
Aug 12, 2031
PregastatPregabalin
150 mg CapsuleAlu/Clear PVC Aclar Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Lupin LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: Lupin Philippines, Inc.
DR-XY45532
Jul 28, 2031
PregastatPregabalin
75 mg CapsuleAlu/Clear PVC Aclar Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Lupin LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: Lupin Philippines, Inc.
DR-XY45531
Jul 28, 2031
PregavPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 14's (Box of 56’s)
RxVAT-exempt
Standard Chem & Pharm Co., Ltd. (Plant II)China
Crisdy-Na Drug CorporationImporter: Standard Chem & Pharm Philippines, Inc.
DRP-8186-01
Oct 29, 2028
Pregeb 150Pregabalin
150 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY44846
Oct 1, 2031
Pregeb 50Pregabalin
50 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY48424
Oct 18, 2027
Pregeb 75Pregabalin
75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals LtdIndia
Torrent Pharma Philippines Inc
DR-XY44845
Oct 1, 2031
PregeronPregabalin
100 mg CapsuleAlu/Alu Blister Pack x 7’s (Box of 14’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-12945
Jul 29, 2028
PreglibestPregabalin
150 mg Capsule
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.
—
DRP-6928-03
Nov 21, 2026
PregmedPregabalin
150 mg CapsuleAlu/ Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
LLOYD LABORATORIES, INC.Philippines
Trader: VITALINK HEALTH PRODUCTS, INC.
DRP-7632
Apr 7, 2030
PregmedPregabalin
75 mg CapsuleAlu PVDC x 10's (Box of 30's and 50's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Foramen Products Corporation
DRP-7631
Sep 23, 2031
PrelicaPregabalin
150 mg CapsuleAlu/PVC/PVDC Blister Pack x 10's (Box of 60's)
RxVAT-exempt
Duopharma (M) Sdn. Bhd.Malaysia
DB (Philippines), Inc.
DR-XY48360
Sep 19, 2027
PrelicaPregabalin
75 mg CapsuleAlu/PVC/PVDC Blister Pack x 10's (Box of 60's)
RxVAT-exempt
Duopharma (M) Sdn. Bhd.Malaysia
Importer: DB (Philippines), Inc.
DR-XY48361
Sep 19, 2027
PreLoc 150Pregabalin
150 mg CapsuleAlu-Alu Blister Pack of 10's (Box of 10's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15589
Aug 7, 2029
PreLoc 75Pregabalin
75mg CapsuleAlu-Alu Blister Pack of 10's (Box of 10's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15636
Aug 13, 2029
Prelynca 150Pregabalin
150 mg CapsulePVC/Alu blister pack x 14's (Box of 2 blister pack x 14's)
RxVAT-exempt
Pharmathen International SAGreece
Metro Drug, Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DR-XY47608
Dec 14, 2026
Prelynca 50Pregabalin
50 mg CapsulePVC/Alu Blister Pack x 7's (Box of 3 blister pack x 7's)
RxVAT-exempt
Pharmathen International SAGreece
Metro Drug, Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DR-XY47610
Jan 11, 2027
Prelynca 75Pregabalin
75 mg Hard Gelatin CapsulePVC/Alu Blister Pack x 14's (Box of 2 blister pack x 14's)
RxVAT-exempt
Pharmathen International SAGreece
Metro Drug, Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd.
DR-XY47609
Dec 14, 2026
PrenaxonPregabalin
150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Steril-Gene Life Sciences (P) Ltd.India
Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd.
DR-XY49059
Apr 23, 2031
PrenaxonPregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Steril-Gene Life Sciences (P) LimitedIndia
Synergen Pharma, Inc.Trader: Synergen Asia Pte. Ltd.
DR-XY49058
Apr 23, 2031
PrenovalinPregabalin
75 mg CapsuleAlu-alu blister pack x 10’s (Box of 30’s and 100’s)
RxVAT-exempt
Vee Excel Drugs and Pharmaceutical Private LimitedIndia
Medinova Pharmaceutical Inc.
DRP-18739
Aug 27, 2031
PrevaPregabalin
75 mg CapsuleAlu/PVC blister pack of 10's Box of 30's and 60's
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
EMCURE PHARMA PHILIPPINES INC.Importer: Medethix, Inc.
DRP-8346-02
Aug 20, 2029
Probal 150Pregabalin
150 mg CapsuleAlu-Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
MEPRO PHARMACEUTICAL Pvt. Ltd.India
MEDETHIX INC.
DRP-9870
Sep 18, 2028
Probal 75Pregabalin
75 mg CapsuleAlu/Alu Blister pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
MEPRO PHARMACEUTICAL Pvt. Ltd.India
MEDETHIX INC.
DRP-9869
Sep 12, 2028
Rebalin 150Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 60's)
RxVAT-exempt
Sunglow Lifescience Private LimitedIndia
Despina Pharma Inc.
DRP-13838
Apr 27, 2028
Rebalin 75Pregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 60's)
RxVAT-exempt
Sunglow Lifescience Private LimitedIndia
Despina Pharma Inc.
DRP-13647
Mar 22, 2028
RegabalinPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 4's (Box of 20's)
RxVAT-exempt
The IBN SINA Pharmaceutical Industry Ltd.Bangladesh
Endure Medical, Inc.
DR-XY45360
May 27, 2031
Regabin 75Pregabalin
75 mg CapsuleAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Macleods Pharmaceuticals LimitedIndia
Macleods Pharmaceuticals Philippines, Inc.
DR-XY48516
Dec 1, 2027
RegobalPregabalin
75 mg CapsuleAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Gracure Pharmaceutical LtdIndia
Despina Pharma Inc.
DRP-15813
Sep 26, 2029
Retabalin-RPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 98's)
RxVAT-exempt
Gracure Pharmaceutical Ltd.India
Reta DrugImporter: Dreamax Incorporated
DRP-8707-02
Feb 25, 2031
RetabalinePregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack X 10's. (Box of 30's and Box of 100's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-13209-06
Dec 29, 2027
RhymaPregabalin
150 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DR-XY44406
Apr 7, 2030
RhymaPregabalin
75 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-15049
Jun 1, 2031
SabalinPregabalin
150 mg CapsulePVC/Alu Blister Pack x 14’s (4 blister pack x 14 capsules)
RxVAT-exempt
Changzhou Pharmaceutical FactoryChina
Luoxin Pharmaceuticals (PH) Corp.
DRP-14798
Jan 13, 2031
SabalinPregabalin
50 mg CapsuleAlu/PVC Blister pack x 14's (Box of 56's)
RxVAT-exempt
Changzhou Pharmaceutical FactoryChina
Luoxin Pharmaceuticals (PH) Corp.
DRP-17572
Feb 2, 2031
SabalinPregabalin
75 mg CapsulePVC/Alu Blister Pack x 14's (4 blister pack x 14 capsules)
RxVAT-exempt
Changzhou Pharmaceutical FactoryChina
Luoxin Pharmaceuticals (PH) Corp
DRP-17499
Jan 13, 2031
StagalinPregabalin
75 mg CapsulePVC / Alu blister x 14's (Box of 56's)
RxVAT-exempt
Standard Chem & Pharm Co., Ltd. (Plant II)China
Standard Chem & Pharm Philippines, Inc..
DRP-8186
Jul 4, 2030
Sunpreg 150Pregabalin
150 mg CapsuleAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15590
Aug 7, 2029
Sunpreg 75Pregabalin
75 mg CapsuleAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-15637
Aug 13, 2029
Topglin 150Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's) x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-12975
Nov 11, 2027
Topglin 75Pregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Baroque Pharmaceuticals Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-13126
Dec 5, 2027
UnbrandedPregabalin
150 mg CapsuleAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 3 blister pack x 10's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-11319
Feb 28, 2032
UnbrandedPregabalin
300 mg Sustained-Release CapsuleAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Theon Pharmaceuticals LimitedIndia
IBERICA VERHEILEN PHARMACEUTICALS GROUP CORP.Importer: VERHEILEN IBERICA HEALTH CARE COMPANY INC.Trader: Farma Iberica SL
DR-XY44955
Dec 11, 2030
UnbrandedPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 50's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
Trader: Terramedic, Inc.
DR-XY44096
Jan 23, 2032
UnbrandedPregabalin
75 mg CapsuleAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Actimed, Inc.Trader: Aldril Pharmaceuticals, Inc.
DRP-15049-01
Jun 1, 2036
UnogabPregabalin
150 mg Capsule
RxVAT-exempt
Rhydburg Pharmaceutical Ltd.
—
DRP-6928-01
Nov 21, 2026
UnogabPregabalin
150 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Macropharma CorporationImporter: Ambica International Corporation
DRP-8024-01
Nov 19, 2028
UnogabPregabalin
75 mg CapsuleAlu/Alu Blister Pack x 7's (Box of 56's)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Macropharma CorporationImporter: Ambica International Corporation
DRP-8025-02
Nov 19, 2028
ValiconPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY47542
Nov 18, 2036
Vexer 150Pregabalin
150 mg CapsuleIn a box of 2 Alu/Alu Blister Pack x 10’s (Box of 1’s)
RxVAT-exempt
Akums Drugs & PharmaceuticalsIndia
VE Pharma IncTrader: Vexxa Lifesciences Pvt. Ltd
DR-XY44601
Jun 26, 2030
Vexer 50Pregabalin
50 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 20’s)
RxVAT-exempt
West Coast Pharmaceutical Works Ltd.India
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DRP-7025
Jan 13, 2030
Vexer 75Pregabalin
75 mg CapsuleAlu-Alu Blister Pack x 10’s Box of 20’s
RxVAT-exempt
Akums Drugs & Pharmaceuticals Ltd.India
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY43500
Jun 27, 2029
ZonikPregabalin
150 mg CapsulePVC/PVDC/Alu Blister Pack x 10's (Box of 50's); PVC/PVDC/Alu Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private LimitedTrader: N/A
DR-XY48469
Nov 17, 2027
ZonikPregabalin
25 mg CapsulePVC/PVDC/Alu Blister Pack x 10's (Box of 50's); PVC/PVDC/Alu Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY48733
May 19, 2028
ZonikPregabalin
50 mg CapsulePVC/PVDC/Alu Blister Pack x 10's (Box of 50's); PVC/PVDC/Alu Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY48732
May 19, 2028
ZonikPregabalin
75 mg CapsulePVC/PVDC/Alu Blister Pack x 10's (Box of 50's); PVC/PVDC/Alu Blister Pack x 14's (Box of 56's)
RxVAT-exempt
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private LimitedTrader: N/A
DR-XY48470
Nov 17, 2027
ZyzyxPregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-6592
Jun 22, 2030
(no brand name)Pregabalin
100 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 1 blister pack x 10 capsules; 3 blister packs x 10 capsules; 10 blister packs x 10 capsules)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp
DRP-12751
Oct 3, 2027
(no brand name)Pregabalin
150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp.
DRP-12422
Aug 8, 2027
(no brand name)Pregabalin
150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
PT. Darya-Varia Laboratoria TbkIndonesia
Ritemed Phils., Inc.
DRP-12517
Aug 31, 2027
(no brand name)Pregabalin
150 mg CapsuleAlu-Alu Blister Pack x 10's (Box of 30's and 60's)
RxVAT-exempt
Akums Drugs & Pharmaceutical Ltd. (Plant I - Solid Oral Dosage facility)India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-8149
May 28, 2031
(no brand name)Pregabalin
150mg CapsuleAlu/Alu Blister Pack x 7's (Box of 5 Blister packs x 7 Capsules)
RxVAT-exempt
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DRP-13540
Mar 8, 2028
(no brand name)Pregabalin
50 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp.
DRP-12420
Aug 8, 2027
(no brand name)Pregabalin
50 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 Capsules; Box of 10 Blister packs x 10 Capsules; Box of 1 Blister pack x 10 Capsules)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
—
DRP-12655
Sep 19, 2027
(no brand name)Pregabalin
50mg CapsuleAlu/Alu Blister Pack x 7's (Box of 5 Blister packs x 7 Capsules)
RxVAT-exempt
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DRP-13542
Mar 8, 2028
(no brand name)Pregabalin
75 mg CapsuleAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-11131
Feb 4, 2027
(no brand name)Pregabalin
75 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp.
DRP-12421
Aug 8, 2027
(no brand name)Pregabalin
75 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
PT. Darya-Varia Laboratoria TbkIndonesia
Ritemed Phils., Inc.
DRP-12516
Aug 31, 2027
(no brand name)Pregabalin
75mg CapsuleAlu/Alu Blister Pack x 7's (Box of 5 Blister packs x 7 Capsules)
RxVAT-exempt
Getz Pharma Pvt. Ltd.Pakistan
Importer: Getz Pharma (Phils.), Inc.
DRP-13541
Mar 8, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg Oral Solution: 20 mg/mL [see Description (11) and How Supplied/Storage and Handling (16)] • Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. (3) • Oral Solution: 20 mg/mL. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Angioedema (e.g., swelling of the throat, head, and neck) can occur, and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue LYRICA immediately in these cases. (5.1)
  • • Hypersensitivity reactions (e.g., hives, dyspnea, and wheezing) can occur. Discontinue LYRICA immediately in these patients. (5.2)
  • • Antiepileptic drugs, including pregabalin, the active ingredient in LYRICA, increase the risk of suicidal thoughts or behavior. (5.3)
  • • Abrupt or rapid discontinuation may increase the risk for seizures. Withdrawal symptoms or suicidal behavior and ideation have been observed after discontinuation. Taper LYRICA gradually over a minimum of 1 week. (5.4)
  • • Respiratory depression: May occur with LYRICA, when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Monitor patients and adjust dosage as appropriate. (5.5)
  • • LYRICA may cause dizziness and somnolence and impair patients’ ability to drive or operate machinery. (5.6)
  • • LYRICA may cause peripheral edema. Exercise caution when co-administering LYRICA and thiazolidinedione antidiabetic agents. (5.7)
5.1 Angioedema

5.1 Angioedema There have been postmarketing reports of angioedema in patients during initial and chronic treatment with LYRICA. Specific symptoms included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There were reports of life-threatening angioedema with respiratory compromise requiring emergency treatment.

Discontinue LYRICA immediately in patients with these symptoms. Exercise caution when prescribing LYRICA to patients who have had a previous episode of angioedema. In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema.

5.2 Hypersensitivity

5.2 Hypersensitivity There have been postmarketing reports of hypersensitivity in patients shortly after initiation of treatment with LYRICA. Adverse reactions included skin redness, blisters, hives, rash, dyspnea, and wheezing. Discontinue LYRICA immediately in patients with these symptoms.

5.3 Suicidal Behavior and Ideation

5.3 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including pregabalin, the active ingredient in LYRICA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Suicidal behavior and ideation have also been reported in patients after discontinuation of pregabalin [see Warnings and Precautions (5.4)].

Monitor patients treated with any AED for any indication for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.

In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED‑treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.

Table 3 shows absolute and relative risk by indication for all evaluated AEDs. Table 3. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Difference: Additional Drug Patients with Events Per 1000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing LYRICA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.

Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

5.4 Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation

5.4 Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation As with all antiepileptic drugs (AEDs), withdraw LYRICA gradually to minimize the potential of increased seizure frequency in patients with seizure disorders. Following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea [see Adverse Reactions (6.2), Drug Abuse and Dependence (9.3)].

Suicidal behavior and ideation have also been reported in patients after discontinuation of pregabalin [see Warnings and Precautions (5.3)]. If LYRICA is discontinued, taper the drug gradually over a minimum of 1 week rather than discontinue the drug abruptly.

5.5 Respiratory Depression

5.5 Respiratory Depression There is evidence from case reports, human studies, and animal studies associating LYRICA with serious, life-threatening, or fatal respiratory depression when co-administered with central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. When the decision is made to co-prescribe LYRICA with another CNS depressant, particularly an opioid, or to prescribe LYRICA to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating LYRICA at a low dose.

The management of respiratory depression may include close observation, supportive measures, and reduction or withdrawal of CNS depressants (including LYRICA). There is more limited evidence from case reports, animal studies, and human studies associating LYRICA with serious respiratory depression, without co-administered CNS depressants or without underlying respiratory impairment.

5.6 Dizziness and Somnolence

5.6 Dizziness and Somnolence LYRICA may cause dizziness and somnolence. Inform patients that LYRICA-related dizziness and somnolence may impair their ability to perform tasks such as driving or operating machinery [see Patient Counseling Information (17)]. In the LYRICA controlled trials in adult patients, dizziness was experienced by 30% of LYRICA-treated patients compared to 8% of placebo-treated patients; somnolence was experienced by 23% of LYRICA-treated patients compared to 8% of placebo-treated patients.

Dizziness and somnolence generally began shortly after the initiation of LYRICA therapy and occurred more frequently at higher doses. Dizziness and somnolence were the adverse reactions most frequently leading to withdrawal (4% each) from controlled studies. In LYRICA-treated patients reporting these adverse reactions in short-term, controlled studies, dizziness persisted until the last dose in 30% and somnolence persisted until the last dose in 42% of patients [see Drug Interactions (7)].

In the LYRICA controlled trials in pediatric patients 4 to less than 17 years of age and 1 month to less than 4 years of age for the treatment of partial-onset seizures, somnolence was reported in 21% and 15% of LYRICA-treated patients compared to 14% and 9% of placebo-treated patients, respectively, and occurred more frequently at higher doses. For patients 1 month to less than 4 years of age, somnolence includes related terms lethargy, sluggishness, and hypersomnia.

5.7 Peripheral Edema

5.7 Peripheral Edema LYRICA treatment may cause peripheral edema. In short-term trials of patients without clinically significant heart or peripheral vascular disease, there was no apparent association between peripheral edema and cardiovascular complications such as hypertension or congestive heart failure. Peripheral edema was not associated with laboratory changes suggestive of deterioration in renal or hepatic function.

In controlled clinical trials in adult patients, the incidence of peripheral edema was 6% in the LYRICA group compared with 2% in the placebo group. In controlled clinical trials, 0.5% of LYRICA patients and 0.2% placebo patients withdrew due to peripheral edema. Higher frequencies of weight gain and peripheral edema were observed in patients taking both LYRICA and a thiazolidinedione antidiabetic agent compared to patients taking either drug alone.

The majority of patients using thiazolidinedione antidiabetic agents in the overall safety database were participants in studies of pain associated with diabetic peripheral neuropathy. In this population, peripheral edema was reported in 3% (2/60) of patients who were using thiazolidinedione antidiabetic agents only, 8% (69/859) of patients who were treated with LYRICA only, and 19% (23/120) of patients who were on both LYRICA and thiazolidinedione antidiabetic agents.

Similarly, weight gain was reported in 0% (0/60) of patients on thiazolidinediones only; 4% (35/859) of patients on LYRICA only; and 7.5% (9/120) of patients on both drugs. As the thiazolidinedione class of antidiabetic drugs can cause weight gain and/or fluid retention, possibly exacerbating or leading to heart failure, exercise caution when co-administering LYRICA and these agents.

Because there are limited data on congestive heart failure patients with New York Heart Association (NYHA) Class III or IV cardiac status, exercise caution when using LYRICA in these patients.

5.8 Weight Gain

5.8 Weight Gain LYRICA treatment may cause weight gain. In LYRICA controlled clinical trials in adult patients of up to 14 weeks, a gain of 7% or more over baseline weight was observed in 9% of LYRICA‑treated patients and 2% of placebo-treated patients. Few patients treated with LYRICA (0.3%) withdrew from controlled trials due to weight gain.

LYRICA associated weight gain was related to dose and duration of exposure but did not appear to be associated with baseline BMI, gender, or age. Weight gain was not limited to patients with edema [see Warnings and Precautions (5.7)]. Although weight gain was not associated with clinically important changes in blood pressure in short-term controlled studies, the long-term cardiovascular effects of LYRICA-associated weight gain are unknown.

Among diabetic patients, LYRICA-treated patients gained an average of 1.6 kg (range: -16 to 16 kg), compared to an average 0.3 kg (range: -10 to 9 kg) weight gain in placebo patients. In a cohort of 333 diabetic patients who received LYRICA for at least 2 years, the average weight gain was 5.2 kg. While the effects of LYRICA-associated weight gain on glycemic control have not been systematically assessed, in controlled and longer-term open label clinical trials with diabetic patients, LYRICA treatment did not appear to be associated with loss of glycemic control (as measured by HbA 1C).

5.9 Tumorigenic Potential

5.9 Tumorigenic Potential In standard preclinical in vivo lifetime carcinogenicity studies of LYRICA, an unexpectedly high incidence of hemangiosarcoma was identified in two different strains of mice [see Nonclinical Toxicology (13.1)]. The clinical significance of this finding is unknown. Clinical experience during LYRICA’s premarketing development provides no direct means to assess its potential for inducing tumors in humans.

In clinical studies across various patient populations, comprising 6396 patient-years of exposure in patients greater than 12 years of age, new or worsening-preexisting tumors were reported in 57 patients. Without knowledge of the background incidence and recurrence in similar populations not treated with LYRICA, it is impossible to know whether the incidence seen in these cohorts is or is not affected by treatment.

5.10 Ophthalmological Effects

5.10 Ophthalmological Effects In controlled studies in adult patients, a higher proportion of patients treated with LYRICA reported blurred vision (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing. Less than 1% of patients discontinued LYRICA treatment due to vision-related events (primarily blurred vision).

Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuity was reduced in 7% of patients treated with LYRICA, and 5% of placebo‑treated patients. Visual field changes were detected in 13% of LYRICA-treated, and 12% of placebo-treated patients.

Funduscopic changes were observed in 2% of LYRICA-treated and 2% of placebo-treated patients. Although the clinical significance of the ophthalmologic findings is unknown, inform patients to notify their physician if changes in vision occur. If visual disturbance persists, consider further assessment. Consider more frequent assessment for patients who are already routinely monitored for ocular conditions [see Patient Counseling Information (17)].

5.11 Creatine Kinase Elevations

5.11 Creatine Kinase Elevations LYRICA treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/L for LYRICA-treated patients and 28 U/L for the placebo patients. In all controlled trials in adult patients across multiple patient populations, 1.5% of patients on LYRICA and 0.7% of placebo patients had a value of creatine kinase at least three times the upper limit of normal.

Three LYRICA‑treated subjects had events reported as rhabdomyolysis in premarketing clinical trials. The relationship between these myopathy events and LYRICA is not completely understood because the cases had documented factors that may have caused or contributed to these events. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if these muscle symptoms are accompanied by malaise or fever.

Discontinue treatment with LYRICA if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.

5.12 Decreased Platelet Count

5.12 Decreased Platelet Count LYRICA treatment was associated with a decrease in platelet count. LYRICA-treated subjects experienced a mean maximal decrease in platelet count of 20 × 10 3 /µL, compared to 11 × 10 3 /µL in placebo patients. In the overall database of controlled trials in adult patients, 2% of placebo patients and 3% of LYRICA patients experienced a potentially clinically significant decrease in platelets, defined as 20% below baseline value and less than 150 × 10 3 /µL.

A single LYRICA‑treated subject developed severe thrombocytopenia with a platelet count less than 20 × 10 3 /µL. In randomized controlled trials, LYRICA was not associated with an increase in bleeding-related adverse reactions.

5.13 PR Interval Prolongation

5.13 PR Interval Prolongation LYRICA treatment was associated with PR interval prolongation. In analyses of clinical trial ECG data in adult patients, the mean PR interval increase was 3-6 msec at LYRICA doses greater than or equal to 300 mg/day. This mean change difference was not associated with an increased risk of PR increase greater than or equal to 25% from baseline, an increased percentage of subjects with on-treatment PR greater than 200 msec, or an increased risk of adverse reactions of second or third degree AV block.

Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications. However, these analyses cannot be considered definitive because of the limited number of patients in these categories.

Drug interactions

Drug or classSeverityEffectWhat to do
Opioids and other CNS depressants (e.g., oxycodone, lorazepam, alcohol)Adjust or monitorAdditive cognitive and motor impairment; serious or fatal respiratory depression reported.Start at the lowest dose and monitor for respiratory depression and sedation when combining.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Since LYRICA is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that LYRICA is unlikely to be involved in significant pharmacokinetic drug interactions.

Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between LYRICA and commonly used antiepileptic drugs [see Clinical Pharmacology (12)].

Pharmacodynamics Multiple oral doses of LYRICA were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when LYRICA was co-administered with these drugs. No clinically important effects on respiration were seen.

Drug Interactions In Vitro Studies Pregabalin, at concentrations that were, in general, 10-times those attained in clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems. In vitro drug interaction studies demonstrate that pregabalin does not induce CYP1A2 or CYP3A4 activity.

Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g., theophylline, caffeine) or CYP3A4 substrates (e.g. midazolam, testosterone) is not anticipated. In Vivo Studies The drug interaction studies described in this section were conducted in healthy adults, and across various patient populations.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Drug Interactions In Vitro Studies Pregabalin, at concentrations that were, in general, 10-times those attained in clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems.

In vitro drug interaction studies demonstrate that pregabalin does not induce CYP1A2 or CYP3A4 activity.

Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g., theophylline, caffeine) or CYP3A4 substrates (e.g. midazolam, testosterone) is not anticipated.

Adverse reactions

Common

  • Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, abnormal thinking (≥5% and twice placebo, adults)

Serious

  • Angioedema
  • Hypersensitivity
  • Suicidal behavior and ideation
  • Respiratory depression (with CNS depressants or respiratory impairment)
  • Adverse reactions after abrupt or rapid discontinuation
  • Creatine kinase elevations
  • Decreased platelet count
  • PR interval prolongation
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are described elsewhere in the labeling: • Angioedema [see Warnings and Precautions (5.1)] • Hypersensitivity [see Warnings and Precautions (5.2)] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.3)] • Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.4)] • Respiratory Depression [see Warnings and Precautions (5.5)] • Dizziness and Somnolence [see Warnings and Precautions (5.6)] • Peripheral Edema [see Warnings and Precautions (5.7)] • Weight Gain [see Warnings and Precautions (5.8)] • Tumorigenic Potential [see Warnings and Precautions (5.9)] • Ophthalmological Effects [see Warnings and Precautions (5.10)] • Creatine Kinase Elevations [see Warnings and Precautions (5.11)] • Decreased Platelet Count [see Warnings and Precautions (5.12)] • PR Interval Prolongation [see Warnings and Precautions (5.13)] Most common adverse reactions (greater than or equal to 5% and twice placebo) in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention). (6.1)
  • Most common adverse reactions (greater than or equal to 5% and twice placebo) in pediatric patients for the treatment of partial‑onset seizures are increased weight and increased appetite. (6.1)
  • To report SUSPECTED …
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In all controlled and uncontrolled trials across various patient populations during the premarketing development of LYRICA, more than 10,000 patients have received LYRICA.

Approximately 5000 patients were treated for 6 months or more, over 3100 patients were treated for 1 year or longer, and over 1400 patients were treated for at least 2 years. Adverse Reactions Most Commonly Leading to Discontinuation in All Premarketing Controlled Clinical Studies In premarketing controlled trials of all adult populations combined, 14% of patients treated with LYRICA and 7% of patients treated with placebo discontinued prematurely due to adverse reactions.

In the LYRICA treatment group, the adverse reactions most frequently leading to discontinuation were dizziness (4%) and somnolence (4%). In the placebo group, 1% of patients withdrew due to dizziness and less than 1% withdrew due to somnolence. Other adverse reactions that led to discontinuation from controlled trials more frequently in the LYRICA group compared to the placebo group were ataxia, confusion, asthenia, thinking abnormal, blurred vision, incoordination, and peripheral edema (1% each).

Most Common Adverse Reactions in All Controlled Clinical Studies in Adults In premarketing controlled trials of all adult patient populations combined (including DPN, PHN, and adult patients with partial-onset seizures), dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and “thinking abnormal” (primarily difficulty with concentration/attention) were more commonly reported by subjects treated with LYRICA than by subjects treated with placebo (greater than or equal to 5% and twice the rate of that seen in placebo). Controlled Studies with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Adverse Reactions Leading to Discontinuation In clinical trials in adults with neuropathic pain associated with diabetic peripheral neuropathy, 9% of patients treated with LYRICA and 4% of patients treated with placebo discontinued prematurely due to adverse reactions.

In the LYRICA treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (3%) and somnolence (2%). In comparison, less than 1% of placebo patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring with greater frequency in the LYRICA group than in the placebo group, were asthenia, confusion, and peripheral edema.

Each of these events led to withdrawal in approximately 1% of patients. Most Common Adverse Reactions Table 4 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 1% of patients with neuropathic pain associated with diabetic neuropathy in the combined LYRICA group for which the incidence was greater in this combined LYRICA group than in the placebo group.

A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”. Table 4. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Body system Preferred term 75 mg/day [N=77] % 150 mg/day [N=212] % 300 mg/day [N=321] % 600 mg/day [N=369] % All PGB PGB: pregabalin [N=979] % Placebo [N=459] % Body as a whole Asthenia 4 2 4 7 5 2 Accidental injury 5 2 2 6 4 3 Back pain 0 2 1 2 2 0 Chest pain 4 1 1 2 2 1 Face edema 0 1 1 2 1 0 Digestive system Dry mouth 3 2 5 7 5 1 Constipation 0 2 4 6 4 2 Flatulence 3 0 2 3 2 1 Metabolic and nutritional disorders Peripheral edema 4 6 9 12 9 2 Weight gain 0 4 4 6 4 0 Edema 0 2 4 2 2 0 Hypoglycemia 1 3 2 1 2 1 Nervous system Dizziness 8 9 23 29 21 5 Somnolence 4 6 13 16 12 3 Neuropathy 9 2 2 5 4 3 Ataxia 6 1 2 4 3 1 Vertigo 1 2 2 4 3 1 Confusion 0 1 2 3 2 1 Euphoria 0 0 3 2 2 0 Incoordination 1 0 2 2 2 0 Thinking abnormal Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 1 0 1 3 2 0 Tremor 1 1 1 2 1 0 Abnormal gait 1 0 1 3 1 0 Amnesia 3 1 0 2 1 0 Nervousness 0 1 1 1 1 0 Respiratory system Dyspnea 3 0 2 2 2 1 Special senses Blurry vision Investigator term; summary level term is amblyopia 3 1 3 6 4 2 Abnormal vision 1 0 1 1 1 0 Controlled Studies in Postherpetic Neuralgia Adverse Reactions Leading to Discontinuation In clinical trials in adults with postherpetic neuralgia, 14% of patients treated with LYRICA and 7% of patients treated with placebo discontinued prematurely due to adverse reactions.

In the LYRICA treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (4%) and somnolence (3%). In comparison, less than 1% of placebo patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring in greater frequency in the LYRICA group than in the placebo group, were confusion (2%), as well as peripheral edema, asthenia, ataxia, and abnormal gait (1% each).

Most Common Adverse Reactions Table 5 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 1% of patients with neuropathic pain associated with postherpetic neuralgia in the combined LYRICA group for which the incidence was greater in this combined LYRICA group than in the placebo group. In addition, an event is included, even if the incidence in the all LYRICA group is not greater than in the placebo group, if the incidence of the event in the 600 mg/day group is more than twice that in the placebo group.

A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”. Overall, 12.4% of all pregabalin-treated patients and 9.0% of all placebo-treated patients had at least one severe event while 8% of pregabalin-treated patients and 4.3% of placebo-treated patients had at least one severe treatment-related adverse event.

Table 5. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia Body system Preferred term 75 mg/d [N=84] % 150 mg/d [N=302] % 300 mg/d [N=312] % 600 mg/d [N=154] % All PGB PGB: pregabalin [N=852] % Placebo [N=398] % Body as a whole Infection 14 8 6 3 7 4 Headache 5 9 5 8 7 5 Pain 5 4 5 5 5 4 Accidental injury 4 3 3 5 3 2 Flu syndrome 1 2 2 1 2 1 Face edema 0 2 1 3 2 1 Digestive system Dry mouth 7 7 6 15 8 3 Constipation 4 5 5 5 5 2 Flatulence 2 1 2 3 2 1 Vomiting 1 1 3 3 2 1 Metabolic and nutritional disorders Peripheral edema 0 8 16 16 12 4 Weight gain 1 2 5 7 4 0 Edema 0 1 2 6 2 1 Musculoskeletal system Myasthenia 1 1 1 1 1 0 Nervous system Dizziness 11 18 31 37 26 9 Somnolence 8 12 18 25 16 5 Ataxia 1 2 5 9 5 1 Abnormal gait 0 2 4 8 4 1 Confusion 1 2 3 7 3 0 Thinking abnormal Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 0 2 1 6 2 2 Incoordination 2 2 1 3 2 0 Amnesia 0 1 1 4 2 0 Speech disorder 0 0 1 3 1 0 Respiratory system Bronchitis 0 1 1 3 1 1 Special senses Blurry vision Investigator term; summary level term is amblyopia 1 5 5 9 5 3 Diplopia 0 2 2 4 2 0 Abnormal vision 0 1 2 5 2 0 Eye Disorder 0 1 1 2 1 0 Urogenital System Urinary Incontinence 0 1 1 2 1 0 Controlled Studies of Adjunctive Therapy for Partial-Onset Seizures in Adult Patients Adverse Reactions Leading to Discontinuation Approximately 15% of patients receiving LYRICA and 6% of patients receiving placebo in trials of adjunctive therapy for partial‑onset seizures discontinued prematurely due to adverse reactions.

In the LYRICA treatment group, the adverse reactions most frequently leading to discontinuation were dizziness (6%), ataxia (4%), and somnolence (3%). In comparison, less than 1% of patients in the placebo group withdrew due to each of these events. Other adverse reactions that led to discontinuation of at least 1% of patients in the LYRICA group and at least twice as frequently compared to the placebo group were asthenia, diplopia, blurred vision, thinking abnormal, nausea, tremor, vertigo, headache, and confusion (which each led to withdrawal in 2% or less of patients).

Most Common Adverse Reactions Table 6 lists all dose-related adverse reactions occurring in at least 2% of all LYRICA-treated patients. Dose-relatedness was defined as the incidence of the adverse event in the 600 mg/day group was at least 2% greater than the rate in both the placebo and 150 mg/day groups. In these studies, 758 patients received LYRICA and 294 patients received placebo for up to 12 weeks.

A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”. Table 6. Dose-related Adverse Reaction Incidence in Controlled Trials of Adjunctive Therapy for Partial-Onset Seizures in Adult Patients Body System Preferred Term 150 mg/d [N=185] % 300 mg/d [N=90] % 600 mg/d [N=395] % All PGB PGB: pregabalin [N=670] Excludes patients who received the 50 mg dose in Study E1. % Placebo [N=294] % Body as a Whole Accidental Injury 7 11 10 9 5 Pain 3 2 5 4 3 Digestive System Increased Appetite 2 3 6 5 1 Dry Mouth 1 2 6 4 1 Constipation 1 1 7 4 2 Metabolic and Nutritional Disorders Weight Gain 5 7 16 12 1 Peripheral Edema 3 3 6 5 2 Nervous System Dizziness 18 31 38 32 11 Somnolence 11 18 28 22 11 Ataxia 6 10 20 15 4 Tremor 3 7 11 8 4 Thinking Abnormal Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 4 8 9 8 2 Amnesia 3 2 6 5 2 Speech Disorder 1 2 7 5 1 Incoordination 1 3 6 4 1 Abnormal Gait 1 3 5 4 0 Twitching 0 4 5 4 1 Confusion 1 2 5 4 2 Myoclonus 1 0 4 2 0 Special Senses Blurred Vision Investigator term; summary level term is amblyopia. 5 8 12 10 4 Diplopia 5 7 12 9 4 Abnormal Vision 3 1 5 4 1 Controlled Study of Adjunctive Therapy for Partial-Onset Seizures in Patients 4 to Less Than 17 Years of Age Adverse Reactions Leading to Discontinuation Approximately 2.5% of patients receiving LYRICA and no patients receiving placebo in trials of adjunctive therapy for partial‑onset seizures discontinued prematurely due to adverse reactions.

In the LYRICA treatment group, the adverse reactions leading to discontinuation were somnolence (3 patients), worsening of epilepsy (1 patient), and hallucination (1 patient). Most Common Adverse Reactions Table 7 lists all dose-related adverse reactions occurring in at least 2% of all LYRICA-treated patients. Dose-relatedness was defined as an incidence of the adverse event in the 10 mg/kg/day group that was at least 2% greater than the rate in both the placebo and 2.5 mg/kg/day groups.

In this study, 201 patients received LYRICA and 94 patients received placebo for up to 12 weeks. A majority of pregabalin-treated patients in the clinical study had adverse reactions with a maximum intensity of “mild” or “moderate”. Table 7. Dose-related Adverse Reaction Incidence in a Controlled Trial in Adjunctive Therapy for Partial‑Onset Seizures in Patients 4 to Less Than 17 Years of Age Abbreviations: N=number of patients; PGB = pregabalin.

Body System Preferred Term 2.5 mg/kg/day 2.5 mg/kg/day: Maximum dose 150 mg/day. Includes patients less than 30 kg for whom dose was adjusted to 3.5 mg/kg/day. [N=104] % 10 mg/kg/day 10 mg/kg/day: Maximum dose 600 mg/day. Includes patients less than 30 kg for whom dose was adjusted to 14 mg/kg/day. [N=97] % All PGB [N=201] % Placebo [N=94] % Gastrointestinal Disorders Salivary Hypersecretion 1 4 2 0 Investigations Weight Increased 4 13 8 4 Metabolism and Nutrition Disorders Increased Appetite 7 10 8 4 Nervous System Disorders Somnolence 17 26 21 14 Controlled Study of Adjunctive Therapy for Partial-Onset Seizures in Patients 1 Month to Less Than 4 Years of Age Most Common Adverse Reactions Table 8 lists all dose-related adverse reactions occurring in at least 2% of all LYRICA-treated patients.

Dose-relatedness was defined as an incidence of the adverse event in the 14 mg/kg/day group that was at least 2% greater than the rate in both the placebo and 7 mg/kg/day groups. In this study, 105 patients received LYRICA and 70 patients received placebo for up to 14 days. Table 8. Dose-related Adverse Reaction Incidence in a Controlled Trial in Adjunctive Therapy for Partial‑Onset Seizures in Patients 1 Month to Less Than 4 Years of Age Abbreviations: N=number of patients; PGB=pregabalin.

Body system Preferred term 7 mg/kg/day [N=71] % 14 mg/kg/day [N=34] % All PGB [N=105] % Placebo [N=70] % Nervous system disorders Somnolence includes related terms including lethargy, sluggishness, and hypersomnia. 13 21 15 9 Infections and infestations Pneumonia 1 9 4 0 Viral infection 3 6 4 3 Controlled Studies with Fibromyalgia Adverse Reactions Leading to Discontinuation In clinical trials of patients with fibromyalgia, 19% of patients treated with pregabalin (150‑600 mg/day) and 10% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (6%) and somnolence (3%).

In comparison, less than 1% of placebo-treated patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were fatigue, headache, balance disorder, and weight increased. Each of these adverse reactions led to withdrawal in approximately 1% of patients.

Most Common Adverse Reactions Table 9 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 2% of patients with fibromyalgia in the ‘all pregabalin’ treatment group for which the incidence was greater than in the placebo treatment group. A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of “mild” or “moderate”.

Table 9. Adverse Reaction Incidence in Controlled Trials in Fibromyalgia System Organ Class Preferred term 150 mg/d [N=132] % 300 mg/d [N=502] % 450 mg/d [N=505] % 600 mg/d [N=378] % All PGB PGB: pregabalin [N=1517] % Placebo [N=505] % Ear and Labyrinth Disorders Vertigo 2 2 2 1 2 0 Eye Disorders Vision blurred 8 7 7 12 8 1 Gastrointestinal Disorders Dry mouth 7 6 9 9 8 2 Constipation 4 4 7 10 7 2 Vomiting 2 3 3 2 3 2 Flatulence 1 1 2 2 2 1 Abdominal distension 2 2 2 2 2 1 General Disorders and Administrative Site Conditions Fatigue 5 7 6 8 7 4 Edema peripheral 5 5 6 9 6 2 Chest pain 2 1 1 2 2 1 Feeling abnormal 1 3 2 2 2 0 Edema 1 2 1 2 2 1 Feeling drunk 1 2 1 2 2 0 Infections and Infestations Sinusitis 4 5 7 5 5 4 Investigations Weight increased 8 10 10 14 11 2 Metabolism and Nutrition Disorders Increased appetite 4 3 5 7 5 1 Fluid retention 2 3 3 2 2 1 Musculoskeletal and Connective Tissue Disorders Arthralgia 4 3 3 6 4 2 Muscle spasms 2 4 4 4 4 2 Back pain 2 3 4 3 3 3 Nervous System Disorders Dizziness 23 31 43 45 38 9 Somnolence 13 18 22 22 20 4 Headache 11 12 14 10 12 12 Disturbance in attention 4 4 6 6 5 1 Balance disorder 2 3 6 9 5 0 Memory impairment 1 3 4 4 3 0 Coordination abnormal 2 1 2 2 2 1 Hypoesthesia 2 2 3 2 2 1 Lethargy 2 2 1 2 2 0 Tremor 0 1 3 2 2 0 Psychiatric Disorders Euphoric Mood 2 5 6 7 6 1 Confusional state 0 2 3 4 3 0 Anxiety 2 2 2 2 2 1 Disorientation 1 0 2 1 2 0 Depression 2 2 2 2 2 2 Respiratory, Thoracic and Mediastinal Disorders Pharyngolaryngeal pain 2 1 3 3 2 2 Controlled Studies in Neuropathic Pain Associated with Spinal Cord Injury Adverse Reactions Leading to Discontinuation In clinical trials of adults with neuropathic pain associated with spinal cord injury, 13% of patients treated with pregabalin and 10% of patients treated with placebo discontinued prematurely due to adverse reactions.

In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were somnolence (3%) and edema (2%). In comparison, none of the placebo-treated patients withdrew due to somnolence and edema. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were fatigue and balance disorder.

Each of these adverse reactions led to withdrawal in less than 2% of patients. Most Common Adverse Reactions Table 10 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 2% of patients for which the incidence was greater than in the placebo treatment group with neuropathic pain associated with spinal cord injury in the controlled trials.

A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of “mild” or “moderate”. Table 10. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Spinal Cord Injury System Organ Class Preferred term PGB PGB: Pregabalin (N=182) Placebo (N=174) % % Ear and labyrinth disorders Vertigo 2.7 1.1 Eye disorders Vision blurred 6.6 1.1 Gastrointestinal disorders Dry mouth 11.0 2.9 Constipation 8.2 5.7 Nausea 4.9 4.0 Vomiting 2.7 1.1 General disorders and administration site conditions Fatigue 11.0 4.0 Edema peripheral 10.4 5.2 Edema 8.2 1.1 Pain 3.3 1.1 Infections and infestations Nasopharyngitis 8.2 4.6 Investigations Weight increased 3.3 1.1 Blood creatine phosphokinase increased 2.7 0 Musculoskeletal and connective tissue disorders Muscular weakness 4.9 1.7 Pain in extremity 3.3 2.3 Neck pain 2.7 1.1 Back pain 2.2 1.7 Joint swelling 2.2 0 Nervous system disorders Somnolence 35.7 11.5 Dizziness 20.9

6.9 Disturbance

6.9 Disturbance in attention 3.8 0 Memory impairment 3.3 1.1 Paresthesia 2.2 0.6 Psychiatric disorders Insomnia 3.8 2.9 Euphoric mood 2.2 0.6 Renal and urinary disorders Urinary incontinence 2.7 1.1 Skin and subcutaneous tissue disorders Decubitus ulcer 2.7 1.1 Vascular disorders Hypertension 2.2 1.1 Hypotension 2.2 0 Other Adverse Reactions Observed During the Clinical Studies of LYRICA Following is a list of treatment-emergent adverse reactions reported by patients treated with LYRICA during all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening.

Events are categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse reactions are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients. Events of major clinical importance are described in the Warnings and Precautions section (5).

Body as a Whole – Frequent: Abdominal pain, Allergic reaction, Fever, Infrequent: Abscess, Cellulitis, Chills, Malaise, Neck rigidity, Overdose, Pelvic pain, Photosensitivity reaction, Rare: Anaphylactoid reaction, Ascites, Granuloma, Hangover effect, Intentional Injury, Retroperitoneal Fibrosis, Shock Cardiovascular System – Infrequent: Deep thrombophlebitis, Heart failure, Hypotension, Postural hypotension, Retinal vascular disorder, Syncope; Rare: ST Depressed, Ventricular Fibrillation Digestive System – Frequent: Gastroenteritis, Increased appetite; Infrequent: Cholecystitis, Cholelithiasis, Colitis, Dysphagia, Esophagitis, Gastritis, Gastrointestinal hemorrhage, Melena, Mouth ulceration, Pancreatitis, Rectal hemorrhage, Tongue edema; Rare: Aphthous stomatitis, Esophageal Ulcer, Periodontal abscess Hemic and Lymphatic System – Frequent: Ecchymosis; Infrequent: Anemia, Eosinophilia, Hypochromic anemia, Leukocytosis, Leukopenia, Lymphadenopathy, Thrombocytopenia; Rare: Myelofibrosis, Polycythemia, Prothrombin decreased, Purpura, Thrombocythemia, Alanine aminotransferase increased, Aspartate aminotransferase increased Metabolic and Nutritional Disorders – Rare: Glucose Tolerance Decreased, Urate Crystalluria Musculoskeletal System – Frequent: Arthralgia, Leg cramps, Myalgia, Myasthenia; Infrequent: Arthrosis; Rare: Chondrodystrophy, Generalized Spasm Nervous System – Frequent: Anxiety, Depersonalization, Hypertonia, Hypoesthesia, Libido decreased, Nystagmus, Paresthesia, Sedation, Stupor, Twitching; Infrequent: Abnormal dreams, Agitation, Apathy, Aphasia, Circumoral paresthesia, Dysarthria, Hallucinations, Hostility, Hyperalgesia, Hyperesthesia, Hyperkinesia, Hypokinesia, Hypotonia, Libido increased, Myoclonus, Neuralgia; Rare: Addiction, Cerebellar syndrome, Cogwheel rigidity, Coma, Delirium, Delusions, Dysautonomia, Dyskinesia, Dystonia, Encephalopathy, Extrapyramidal syndrome, Guillain-Barré syndrome, Hypalgesia, Intracranial hypertension, Manic reaction, Paranoid reaction, Peripheral neuritis, Personality disorder, Psychotic depression, Schizophrenic reaction, Sleep disorder, Torticollis, Trismus Respiratory System – Rare: Apnea, Atelectasis, Bronchiolitis, Hiccup, Laryngismus, Lung edema, Lung fibrosis, Yawn Skin and Appendages – Frequent: Pruritus, Infrequent: Alopecia, Dry skin, Eczema, Hirsutism, Skin ulcer, Urticaria, Vesiculobullous rash; Rare: Angioedema, Exfoliative dermatitis, Lichenoid dermatitis, Melanosis, Nail Disorder, Petechial rash, Purpuric rash, Pustular rash, Skin atrophy, Skin necrosis, Skin nodule, Stevens-Johnson syndrome, Subcutaneous nodule Special senses – Frequent: Conjunctivitis, Diplopia, Otitis media, Tinnitus; Infrequent: Abnormality of accommodation, Blepharitis, Dry eyes, Eye hemorrhage, Hyperacusis, Photophobia, Retinal edema, Taste loss, Taste perversion; Rare: Anisocoria, Blindness, Corneal ulcer, Exophthalmos, Extraocular palsy, Iritis, Keratitis, Keratoconjunctivitis, Miosis, Mydriasis, Night blindness, Ophthalmoplegia, Optic atrophy, Papilledema, Parosmia, Ptosis, Uveitis Urogenital System – Frequent: Anorgasmia, Impotence, Urinary frequency, Urinary incontinence; Infrequent: Abnormal ejaculation, Albuminuria, Amenorrhea, Dysmenorrhea, Dysuria, Hematuria, Kidney calculus, Leukorrhea, Menorrhagia, Metrorrhagia, Nephritis, Oliguria, Urinary retention, Urine abnormality; Rare: Acute kidney failure, Balanitis, Bladder Neoplasm, Cervicitis, Dyspareunia, Epididymitis, Female lactation, Glomerulitis, Ovarian disorder, Pyelonephritis Comparison of Gender and Race The overall adverse event profile of pregabalin was similar between women and men. There are insufficient data to support a statement regarding the distribution of adverse experience reports by race.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of LYRICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Nervous System Disorders – Headache Gastrointestinal Disorders – Nausea, Diarrhea Reproductive System and Breast Disorders – Gynecomastia, Breast Enlargement Skin and subcutaneous tissue disorders – Bullous pemphigoid There are postmarketing reports of life-threatening or fatal respiratory depression in patients taking LYRICA with opioids or other CNS depressants, or in the setting of underlying respiratory impairment.

In addition, there are postmarketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when LYRICA was co-administered with medications that have the potential to produce constipation, such as opioid analgesics. There are postmarketing reports of withdrawal symptoms after discontinuation of pregabalin.

Reported adverse reactions include, but are not limited to, seizures, depression, suicidal ideation and behavior, agitation, confusion, disorientation, psychotic symptoms, anxiety, insomnia, nausea, pain, sweating, tremor, headache, dizziness, malaise, and diarrhea.

Adverse reaction frequency tables (US label) US FDA label
Table 4. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Body system Preferred term75 mg/day [N=77] %150 mg/day [N=212] %300 mg/day [N=321] %600 mg/day [N=369] %All PGBPGB: pregabalin [N=979] %Placebo [N=459] %
Body as a whole
Asthenia424752
Accidental injury522643
Back pain021220
Chest pain411221
Face edema011210
Digestive system
Dry mouth325751
Constipation024642
Flatulence302321
Metabolic and nutritional disorders
Peripheral edema4691292
Weight gain044640
Edema024220
Hypoglycemia132121
Nervous system
Dizziness892329215
Somnolence461316123
Neuropathy922543
Ataxia612431
Vertigo122431
Confusion012321
Euphoria003220
Incoordination102220
Thinking abnormalThinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 101320
Tremor111210
Abnormal gait101310
Amnesia310210
Nervousness011110
Respiratory system
Dyspnea302221
Special senses
Blurry visionInvestigator term; summary level term is amblyopia313642
Abnormal vision101110
Table 5. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia
Body system Preferred term75 mg/d [N=84] %150 mg/d [N=302] %300 mg/d [N=312] %600 mg/d [N=154] %All PGBPGB: pregabalin [N=852] %Placebo [N=398] %
Body as a whole
Infection1486374
Headache595875
Pain545554
Accidental injury433532
Flu syndrome122121
Face edema021321
Digestive system
Dry mouth7761583
Constipation455552
Flatulence212321
Vomiting113321
Metabolic and nutritional disorders
Peripheral edema081616124
Weight gain125740
Edema012621
Musculoskeletal system
Myasthenia111110
Nervous system
Dizziness11183137269
Somnolence8121825165
Ataxia125951
Abnormal gait024841
Confusion123730
Thinking abnormalThinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 021622
Incoordination221320
Amnesia011420
Speech disorder001310
Respiratory system
Bronchitis011311
Special senses
Blurry visionInvestigator term; summary level term is amblyopia155953
Diplopia022420
Abnormal vision012520
Eye Disorder011210
Urogenital System
Urinary Incontinence011210
Table 6. Dose-related Adverse Reaction Incidence in Controlled Trials of Adjunctive Therapy for Partial-Onset Seizures in Adult Patients
Body System Preferred Term150 mg/d[N=185]%300 mg/d[N=90]%600 mg/d[N=395]%All PGBPGB: pregabalin [N=670]Excludes patients who received the 50 mg dose in Study E1. %Placebo[N=294]%
Body as a Whole
Accidental Injury7111095
Pain32543
Digestive System
Increased Appetite 23651
Dry Mouth12641
Constipation11742
Metabolic and Nutritional Disorders
Weight Gain5716121
Peripheral Edema33652
Nervous System
Dizziness1831383211
Somnolence1118282211
Ataxia61020154
Tremor371184
Thinking AbnormalThinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. 48982
Amnesia32652
Speech Disorder12751
Incoordination13641
Abnormal Gait13540
Twitching04541
Confusion12542
Myoclonus10420
Special Senses
Blurred VisionInvestigator term; summary level term is amblyopia.5812104
Diplopia571294
Abnormal Vision31541
Table 7. Dose-related Adverse Reaction Incidence in a Controlled Trial in Adjunctive Therapy for Partial‑Onset Seizures in Patients 4 to Less Than 17 Years of Age
Abbreviations: N=number of patients; PGB = pregabalin.
Body SystemPreferred Term2.5 mg/kg/day2.5 mg/kg/day: Maximum dose 150 mg/day. Includes patients less than 30 kg for whom dose was adjusted to 3.5 mg/kg/day. [N=104]%10 mg/kg/day10 mg/kg/day: Maximum dose 600 mg/day. Includes patients less than 30 kg for whom dose was adjusted to 14 mg/kg/day.[N=97]%All PGB[N=201]%Placebo[N=94]%
Gastrointestinal Disorders
Salivary Hypersecretion1420
Investigations
Weight Increased41384
Metabolism and Nutrition Disorders
Increased Appetite71084
Nervous System Disorders
Somnolence17262114
Table 8. Dose-related Adverse Reaction Incidence in a Controlled Trial in Adjunctive Therapy for Partial‑Onset Seizures in Patients 1 Month to Less Than 4 Years of Age
Abbreviations: N=number of patients; PGB=pregabalin.
Body systemPreferred term7 mg/kg/day[N=71]%14 mg/kg/day[N=34]%All PGB[N=105]%Placebo[N=70]%
Nervous system disorders
Somnolenceincludes related terms including lethargy, sluggishness, and hypersomnia.1321159
Infections and infestations
Pneumonia1940
Viral infection3643
Table 9. Adverse Reaction Incidence in Controlled Trials in Fibromyalgia
System Organ ClassPreferred term150 mg/d [N=132] %300 mg/d [N=502] %450 mg/d [N=505] %600 mg/d [N=378] %All PGBPGB: pregabalin [N=1517] %Placebo [N=505] %
Ear and Labyrinth Disorders
Vertigo222120
Eye Disorders
Vision blurred8771281
Gastrointestinal Disorders
Dry mouth769982
Constipation4471072
Vomiting233232
Flatulence112221
Abdominal distension222221
General Disorders and Administrative Site Conditions
Fatigue576874
Edema peripheral556962
Chest pain211221
Feeling abnormal132220
Edema121221
Feeling drunk121220
Infections and Infestations
Sinusitis457554
Investigations
Weight increased 8101014112
Metabolism and Nutrition Disorders
Increased appetite435751
Fluid retention233221
Musculoskeletal and Connective Tissue Disorders
Arthralgia433642
Muscle spasms244442
Back pain234333
Nervous System Disorders
Dizziness23314345389
Somnolence13182222204
Headache111214101212
Disturbance in attention446651
Balance disorder236950
Memory impairment134430
Coordination abnormal212221
Hypoesthesia223221
Lethargy221220
Tremor013220
Psychiatric Disorders
Euphoric Mood256761
Confusional state023430
Anxiety222221
Disorientation102120
Depression222222
Respiratory, Thoracic and Mediastinal Disorders
Pharyngolaryngeal pain213322
Table 10. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Spinal Cord Injury
System Organ ClassPreferred termPGBPGB: Pregabalin (N=182)Placebo (N=174)
%%
Ear and labyrinth disorders
Vertigo2.71.1
Eye disorders
Vision blurred6.61.1
Gastrointestinal disorders
Dry mouth11.02.9
Constipation8.25.7
Nausea4.94.0
Vomiting2.71.1
General disorders and administration site conditions
Fatigue11.04.0
Edema peripheral10.45.2
Edema8.21.1
Pain3.31.1
Infections and infestations
Nasopharyngitis8.24.6
Investigations
Weight increased3.31.1
Blood creatine phosphokinase increased2.70
Musculoskeletal and connective tissue disorders
Muscular weakness4.91.7
Pain in extremity3.32.3
Neck pain2.71.1
Back pain2.21.7
Joint swelling2.20
Nervous system disorders
Somnolence35.711.5
Dizziness20.96.9
Disturbance in attention3.80
Memory impairment3.31.1
Paresthesia2.20.6
Psychiatric disorders
Insomnia3.82.9
Euphoric mood2.20.6
Renal and urinary disorders
Urinary incontinence2.71.1
Skin and subcutaneous tissue disorders
Decubitus ulcer2.71.1
Vascular disorders
Hypertension2.21.1
Hypotension2.20

Monitoring parameters

  • Dizziness, somnolence, edema, respiratory depression (especially with opioids or other central nervous system depressants). Altered mental status and falls are more common in hemodialysis patients (Ishida 2018). Kidney
  • Creatinine clearance for dosing
  • Sedation, dizziness and respiratory status (especially with opioids or kidney impairment)
  • Edema and weight
  • Mood changes and suicidal thoughts
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to LYRICA during pregnancy. To provide information regarding the effects of in utero exposure to LYRICA, physicians are advised to recommend that pregnant patients taking LYRICA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. Risk Summary Observational studies on the use of Lyrica during pregnancy suggest a possible small increase in the rate of overall major birth defects, but there was no consistent or specific pattern of major birth defects identified (see Data).

Available postmarketing data on miscarriage and other maternal, fetal, and long term developmental adverse effects were insufficient to identify risk associated with pregabalin. Postmarketing data suggest that extended gabapentinoid use with opioids close to delivery may increase the risk of neonatal withdrawal versus opioids alone (see Clinical Considerations).

There are no comparative epidemiologic studies evaluating this association. Therefore, it is not known whether exposure to pregabalin alone late in pregnancy may cause withdrawal signs and symptoms. In animal reproduction studies, increased incidences of fetal structural abnormalities and other manifestations of developmental toxicity, including skeletal malformations, retarded ossification, and decreased fetal body weight were observed in the offspring of rats and rabbits given pregabalin orally during organogenesis, at doses that produced plasma pregabalin exposures (AUC) greater than or equal to 16 times human exposure at the maximum recommended dose (MRD) of 600 mg/day (see Data).

In an animal development study, lethality, growth retardation, and nervous and reproductive system functional impairment were observed in the offspring of rats given pregabalin during gestation and lactation. The no-effect dose for developmental toxicity was approximately twice the human exposure at MRD. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Neonatal withdrawal syndrome has been reported in newborns exposed to gabapentinoids in utero for an extended period of time when also exposed to opioids close to delivery.

Neonatal withdrawal signs and symptoms reported have included tachypnea, vomiting, diarrhea, hypertonia, irritability, sneezing, poor feeding, hyperactivity, abnormal sleep pattern, and tremor. Reported signs and symptoms that may also be related to withdrawal include tongue thrusting, wandering eye movements while awake, back arching, and continuous extremity movements.

Observe neonates exposed to LYRICA and opioids for signs and symptoms of neonatal withdrawal and manage accordingly. Data Human Data One database study, which included over 2,700 pregnancies exposed to pregabalin (monotherapy) during the first trimester compared to 3,063,251 pregnancies unexposed to antiepileptics demonstrated prevalence ratios for major malformations overall of 1.14 (CI 95% 0.96-1.35) for pregabalin, 1.29 (CI 95% 1.01-1.65) for lamotrigine, 1.39 (CI 95% 1.07-1.82) for duloxetine, and 1.24 (CI 95% 1.00-1.54) for exposure to either lamotrigine or duloxetine.

Important study limitations include uncertainty of whether women who filled a prescription took the medication and inability to adequately control for the underlying disease and other potential confounders. A published study included results from two separate databases. One database, which included 353 pregnancies exposed to pregabalin (monotherapy) during the first trimester compared to 368,489 pregnancies unexposed to antiepileptics, showed no increase in risk of major birth defects; adjusted relative risk 0.87 (CI 95% 0.53-1.42).

The second database, which included 118 pregnancies exposed to pregabalin (monotherapy) during the first trimester compared to 380,347 pregnancies unexposed to antiepileptics, suggested a small increase in risk of major birth defects; adjusted relative risk 1.26 (CI 95% 0.64-2.49). The risk estimates crossed the null, and the study had limitations similar to the prior study.

Other published epidemiologic studies reported inconsistent findings. No specific pattern of birth defects was identified across studies. All of the studies had limitations due to their retrospective design. Animal Data When pregnant rats were given pregabalin (500, 1250, or 2500 mg/kg) orally throughout the period of organogenesis, incidences of specific skull alterations attributed to abnormally advanced ossification (premature fusion of the jugal and nasal sutures) were increased at greater than or equal to 1250 mg/kg, and incidences of skeletal variations and retarded ossification were increased at all doses.

Fetal body weights were decreased at the highest dose. The low dose in this study was associated with a plasma exposure (AUC) approximately 17 times human exposure at the MRD of 600 mg/day. A no-effect dose for rat embryo-fetal developmental toxicity was not established. When pregnant rabbits were given LYRICA (250, 500, or 1250 mg/kg) orally throughout the period of organogenesis, decreased fetal body weight and increased incidences of skeletal malformations, visceral variations, and retarded ossification were observed at the highest dose.

The no-effect dose for developmental toxicity in rabbits (500 mg/kg) was associated with a plasma exposure approximately 16 times human exposure at the MRD. In a study in which female rats were dosed with LYRICA (50, 100, 250, 1250, or 2500 mg/kg) throughout gestation and lactation, offspring growth was reduced at greater than or equal to 100 mg/kg and offspring survival was decreased at greater than or equal to 250 mg/kg.

The effect on offspring survival was pronounced at doses greater than or equal to 1250 mg/kg, with 100% mortality in high-dose litters. When offspring were tested as adults, neurobehavioral abnormalities (decreased auditory startle responding) were observed at greater than or equal to 250 mg/kg and reproductive impairment (decreased fertility and litter size) was seen at 1250 mg/kg.

The no-effect dose for pre- and postnatal developmental toxicity in rats (50 mg/kg) produced a plasma exposure approximately 2 times human exposure at the MRD. In the prenatal-postnatal study in rats, pregabalin prolonged gestation and induced dystocia at exposures greater than or equal to 50 times the mean human exposure (AUC (0–24) of 123 µg∙hr/mL) at the MRD.

Mechanism of action

12.1 Mechanism of Action LYRICA (pregabalin) binds with high affinity to the alpha 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha 2 -delta subunit may be involved in pregabalin’s anti-nociceptive and antiseizure effects in animals.

In animal models of nerve damage, pregabalin has been shown to reduce calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord, possibly by disrupting alpha 2 -delta containing-calcium channel trafficking and/or reducing calcium currents. Evidence from other animal models of nerve damage and persistent pain suggest the anti-nociceptive activities of pregabalin may also be mediated through interactions with descending noradrenergic and serotonergic pathways originating from the brainstem that modulate pain transmission in the spinal cord.

While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA A, GABA B, or benzodiazepine receptors, does not augment GABA A responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport.

Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.

US FDA label

Pharmacokinetics

Key PK parameters

Bioavailability≥90%, dose independent
Time to peakWithin 1.5 hours (fasting)
Half-lifeAbout 6.3 hours
Half-life in kidney failure (ESKD) kidneyProlonged in proportion to falling CrCl (clearance about proportional to CrCl); about 50% removed by a 4-hour HD (label; Randinitis 2003).
Volume of distributionAbout 0.5 L/kg
Protein bindingNot bound
Metabolism (CYP, transporters)Negligible (N-methyl metabolite 0.9% of dose)
Active metabolitesNone
Renal excretion kidneyAbout 90% unchanged in urine
Dialyzability kidneyYes: about 50% removed in a 4-hour hemodialysis (label).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

12.3 Pharmacokinetics Pregabalin is well absorbed after oral administration, is eliminated largely by renal excretion, and has an elimination half-life of about 6 hours.

Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in subjects with normal renal function.

Mean renal clearance was estimated to be 67.0 to 80.9 mL/min in young healthy subjects.

The mean t ½ is 3 to 4 hours in pediatric subjects up to 6 years of age, and 4 to 6 hours in those 7 years of age and older.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Pregabalin is well absorbed after oral administration, is eliminated largely by renal excretion, and has an elimination half-life of about 6 hours. Absorption and Distribution Following oral administration of LYRICA capsules under fasting conditions, peak plasma concentrations occur within 1.5 hours.

Pregabalin oral bioavailability is greater than or equal to 90% and is independent of dose. Following single- (25 to 300 mg) and multiple-dose (75 to 900 mg/day) administration, maximum plasma concentrations (C max) and area under the plasma concentration-time curve (AUC) values increase linearly. Following repeated administration, steady state is achieved within 24 to 48 hours.

Multiple-dose pharmacokinetics can be predicted from single-dose data. The rate of pregabalin absorption is decreased when given with food, resulting in a decrease in C max of approximately 25% to 30% and an increase in T max to approximately 3 hours. However, administration of pregabalin with food has no clinically relevant effect on the total absorption of pregabalin.

Therefore, pregabalin can be taken with or without food. Pregabalin does not bind to plasma proteins. The apparent volume of distribution of pregabalin following oral administration is approximately 0.5 L/kg. Pregabalin is a substrate for system L transporter which is responsible for the transport of large amino acids across the blood brain barrier.

Although there are no data in humans, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. In addition, pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. Metabolism and Elimination Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabeled pregabalin, approximately 90% of the administered dose was recovered in the urine as unchanged pregabalin.

The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, pregabalin (S‑enantiomer) did not undergo racemization to the R-enantiomer in mice, rats, rabbits, or monkeys. Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in subjects with normal renal function.

Mean renal clearance was estimated to be 67.0 to 80.9 mL/min in young healthy subjects. Because pregabalin is not bound to plasma proteins this clearance rate indicates that renal tubular reabsorption is involved. Pregabalin elimination is nearly proportional to creatinine clearance (CLcr) [see Dosage and Administration (2.7)].

Pharmacokinetics in Specific Populations Race In population pharmacokinetic analyses of the clinical studies in various populations, the pharmacokinetics of LYRICA were not significantly affected by race (Caucasians, Blacks, and Hispanics). Gender Population pharmacokinetic analyses of the clinical studies showed that the relationship between daily dose and LYRICA drug exposure is similar between genders.

Renal Impairment and Hemodialysis Pregabalin clearance is nearly proportional to creatinine clearance (CLcr). Dosage reduction in patients with renal dysfunction is necessary. Pregabalin is effectively removed from plasma by hemodialysis. Following a 4-hour hemodialysis treatment, plasma pregabalin concentrations are reduced by approximately 50%.

For patients on hemodialysis, dosing must be modified [see Dosage and Administration (2.7)]. Elderly Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in CLcr. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function [see Dosage and Administration (2.7)].

Pediatric Pharmacokinetics Pediatric Patients (3 months to less than 17 years of age) Pregabalin pharmacokinetics were evaluated in 358 pediatric patients 3 months to less than 17 years of age with partial‑onset seizures at dose levels of 2.5, 5, 10, and 15 mg/kg/day after single and multiple oral administration of pregabalin. Following oral administration, pregabalin reaches peak plasma concentration at 0.5 hours to 2 hours in the fasted state.

Both apparent clearance (CL/F) and apparent volume of distribution increase as body weight increases. A weight-based dosing regimen is necessary to achieve pregabalin exposures in pediatric patients 1 month to less than 17 years of age similar to those observed in adults treated for partial‑onset seizures at effective doses [see Dosage and Administration (2.4)].

The mean t ½ is 3 to 4 hours in pediatric subjects up to 6 years of age, and 4 to 6 hours in those 7 years of age and older. Pregabalin CL/F is nearly proportional to CLcr (mL/min). The relationship is similar in pediatric and adult subjects. When normalized per body weight, CL/F (mL/min/kg) in pediatric subjects weighing less than 30 kg is approximately 40% higher in comparison to subjects weighing greater than or equal to 30 kg [see Dosage and Administration (2.4)].

Drug Interactions In Vitro Studies Pregabalin, at concentrations that were, in general, 10-times those attained in clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems. In vitro drug interaction studies demonstrate that pregabalin does not induce CYP1A2 or CYP3A4 activity.

Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g., theophylline, caffeine) or CYP3A4 substrates (e.g. midazolam, testosterone) is not anticipated. In Vivo Studies The drug interaction studies described in this section were conducted in healthy adults, and across various patient populations.

Gabapentin The pharmacokinetic interactions of pregabalin and gabapentin were investigated in 12 healthy subjects following concomitant single-dose administration of 100-mg pregabalin and 300-mg gabapentin and in 18 healthy subjects following concomitant multiple-dose administration of 200-mg pregabalin every 8 hours and 400-mg gabapentin every 8 hours. Gabapentin pharmacokinetics following single- and multiple-dose administration were unaltered by pregabalin coadministration.

The extent of pregabalin absorption was unaffected by gabapentin coadministration, although there was a small reduction in rate of absorption. Oral Contraceptive Pregabalin coadministration (200 mg three times a day) had no effect on the steady-state pharmacokinetics of norethindrone and ethinyl estradiol (1 mg/35 µg, respectively) in healthy subjects.

Lorazepam Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of lorazepam single-dose pharmacokinetics and single-dose administration of lorazepam (1 mg) had no effect on the steady-state pharmacokinetics of pregabalin. Oxycodone Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of oxycodone single-dose pharmacokinetics.

Single-dose administration of oxycodone (10 mg) had no effect on the steady-state pharmacokinetics of pregabalin. Ethanol Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of ethanol single-dose pharmacokinetics and single-dose administration of ethanol (0.7 g/kg) had no effect on the steady-state pharmacokinetics of pregabalin.

Phenytoin, carbamazepine, valproic acid, and lamotrigine Steady-state trough plasma concentrations of phenytoin, carbamazepine and carbamazepine 10,11 epoxide, valproic acid, and lamotrigine were not affected by concomitant pregabalin (200 mg three times a day) administration. Population pharmacokinetic analyses in patients treated with pregabalin and various concomitant medications suggest the following: Therapeutic class Specific concomitant drug studied Concomitant drug has no effect on the pharmacokinetics of pregabalin Hypoglycemics Glyburide, insulin, metformin Diuretics Furosemide Antiepileptic Drugs Tiagabine Concomitant drug has no effect on the pharmacokinetics of pregabalin and pregabalin has no effect on the pharmacokinetics of concomitant drug Antiepileptic Drugs Carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproic acid

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Lyrica · Viatris Specialty LLC [US FDA-approved label, version 18, April 15, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Viatris Specialty LLC. (2025). Lyrica (pregabalin) [Prescribing information; US FDA-approved label, NDA021446, set ID d4734e7d-5079-455e-8ff5-8f4539c998a9, version effective April 15, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9
  4. Ishida, J. H., McCulloch, C. E., Steinman, M. A., Grimes, B. A., & Johansen, K. L. (2018). Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. Journal of the American Society of Nephrology, 29(7), 1970–1978. https://doi.org/10.1681/ASN.2018010096
  5. Muanda, F. T., Weir, M. A., Ahmadi, F., Sontrop, J. M., Cowan, A., Fleet, J. L., Blake, P. G., & Garg, A. X. (2022). Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: A population-based cohort study. American Journal of Kidney Diseases, 80(1), 98–107.e1. https://doi.org/10.1053/j.ajkd.2021.11.007
  6. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
  7. Randinitis, E. J., Posvar, E. L., Alvey, C. W., Sedman, A. J., Cook, J. A., & Bockbrader, H. N. (2003). Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Journal of Clinical Pharmacology, 43(3), 277–283. https://doi.org/10.1177/0091270003251119

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .